

**CURRICULUM VITAE**  
**Joseph P Costantino, Dr.P.H.**  
**University of Pittsburgh**

<b>Business Address:</b>	201 N Craig Street Suite 350 Pittsburgh, PA 15213	<b>Business Phone:</b>	(412) 383-2638
<b>Email Address:</b>	costan@pitt.edu	<b>Home Address:</b>	3909 Ridgemont Court Murrysville, PA 15668
<b>Home Phone:</b>	(724) 327-3211	<b>Citizenship:</b>	United States of America

**EDUCATION and TRAINING**

**Undergraduate**

6/1972	Bethany College Bethany, WV	BS Biology
--------	--------------------------------	---------------

**Graduate**

4/1976	University of Pittsburgh, Graduate School of Public Health Pittsburgh, PA	DrPH Epidemiology
--------	---	----------------------

4/1974	University of Pittsburgh, Graduate School of Public Health Pittsburgh, PA	MPH Epidemiology
--------	---	---------------------

**APPOINTMENTS and POSITIONS**

**Academic**

3/2014 - Present	NRG Oncology Cooperative Group Pittsburgh, Pennsylvania	Director, NRG Oncology Statistics and Data Management Center
3/2004 - 2/2014	NSABP Biostatistical Center Pittsburgh, Pennsylvania	Director, NSABP Biostatistical Center
2/2002 - Present	University of Pittsburgh, Graduate School of Public Health Pittsburgh, Pennsylvania	Professor of Biostatistics with Tenure Department of Biostatistics
10/1998 - 1/2002	University of Pittsburgh, Graduate School of Public Health Pittsburgh, Pennsylvania	Associate Professor of Biostatistics with Tenure Department of Biostatistics
9/1995 - 3/2003	NSABP Biostatistical Center Pittsburg, Pennsylvania	Associate Director, NSABP Biostatistical Center

8/1995 - 9/1998	University of Pittsburgh, Graduate School of Public Health Pittsburgh, Pennsylvania	Associate Professor of Biostatistics Department of Biostatistics
9/1991 - 9/1995	NSABP Biostatistical Center Pittsburgh, Pennsylvania	Coordinating Statistician, Breast Cancer Prevention Research
7/1985 - 7/1995	University of Pittsburgh, Graduate School of Public Health Pittsburgh, Pennsylvania	Assistant Professor of Biostatistics Department of Biostatistics
9/1984 - 6/1989	University of Pittsburgh, Graduate School of Public Health Clinical Trial of Beta Carotene and Lung Cancer Pittsburgh, Pennsylvania	Director, Beta Carotene Biostatistical Center
1/1984 - 8/1991	NSABP Biostatistical Center Pittsburgh, Pennsylvania	Project Statistician
9/1983 - 6/1985	University of Pittsburgh, Graduate School of Public Health Pittsburgh, Pennsylvania	Adjunct Assistant Professor of Biostatistics and Epidemiology Department of Biostatistics
5/1977 - 9/1983	University of Pittsburgh, Graduate School of Public Health Pittsburgh, Pennsylvania	Adjunct Instructor of Epidemiology Department of Epidemiology
6/1976 - 5/1977	University of Pittsburgh, Graduate School of Public Health Pittsburgh, Pennsylvania	Instructor of Epidemiology Department of Epidemiology
<b>Non-Academic</b>		
5/1977 - 8/1977	Allegheny County Health Department Pittsburgh, Pennsylvania	Chief of Epidemiology
9/1977 - 2/1979	Allegheny County Health Department Pittsburgh, Pennsylvania	Deputy Director of Medical Services
3/1979 - 6/1980	Allegheny County Health Department Pittsburgh, Pennsylvania	Executive Assistant Director
7/1980 - 12/1981	Bituminous Coal Research, Inc. Monroeville, Pennsylvania	Supervisor, Health Effects Research

1/1982 - 10/1984      BCR National Laboratory      Manager, Environmental  
Monroeville, Pennsylvania      and Occupational Health  
Research

### **MEMBERSHIP in PROFESSIONAL and SCIENTIFIC SOCIETIES**

2001 - Present      Member, American Society of Clinical Oncology  
1987 - Present      Member, Delta Omega Public Health Honor Society  
1985 - Present      Member, Biometric Society, ENAR  
1985 - Present      Member, Society for Clinical Trials  
1984 - Present      Member, American Statistical Association  
1980 - Present      Member, Society for Epidemiologic Research  
1977 - Present      Member, American College of Epidemiology  
1977 - Present      Member, American Public Health Association

### **HONORS and AWARDS**

2005      Distinguish Alumni, Graduate School of Public Health, University  
of Pittsburgh  
1990 - 1991      President, Delta Omega, Omicron Chapter  
1989 - 1990      President-Elect, Delta Omega, Omicron Chapter  
1989 - 1991      RJ Lee, Environmental Health Training Award  
1987      Delta Omega, Public Health Honor Society

### **PUBLICATIONS**

#### **Peer-reviewed Publications**

1. Land SR, Walcott FL, Liu Q, Wickerham L, Costantino JP, Ganz PA. Symptoms and QOL as predictors of chemoprevention adherence in NRG Oncology/NSABP Trial P-1. *J Natl Cancer Instit.* 2016 Apr 1; 108 (4):djv365. PMID: 26615179. doi: 10.1093/jnci/djv365.
2. Cecchini RS, Swain SW, Costantino JP, Rastogi P, Jeong JH, Anderson SJ, Tang G, Geyer CE, Lembersky BC, Romond EH, Paterson AH, Wolmark N. Body mass index at diagnosis and breast cancer survival prognosis in clinical trial populations from NRG Oncology/NSABP B-30,B-31, B-34 and B-38. *Cancer Epidemiol Biomarker Prev.* 2016 Jan 25; 25 (1):51-9. PMID: 26545405. doi: 10.1158/1055-9965.EPI-15-0334-T.
3. Liu Q, Tang G, Costantino JP, Chang CH. Robust prediction of the cumulative incidence function under non-proportional subdistribution hazards. *Can J Stat.* 2016; 44 (2):127-141.
4. Ganz PA, Cecchini RS, Julian TB, Margolese R, Costantino JP, Vallow LA, Albain KS, Whitworth PW, Cianfrocca ME, Brufsky AM, Gross HM, Soori GS, Hopkins JO, Fehrenbacher L, Sturtz K, Wozniak TF, Seay TE, Mamounas EP, Wolmark N. Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): A randomised, double-blind, phase 3 clinical trial. *Lancet.* 2015 Dec 10; online. PMID: 26686960. doi: [http://dx.doi.org/10.1016/S0140-6736\(15\)01169-1](http://dx.doi.org/10.1016/S0140-6736(15)01169-1).

5. Margolese L, Cecchini RS, Julian TB, Ganz PA, Costantino JP, Vallow LA, Albain KS, Whitworth PW, Cianfrocca ME, Brufsky AM, Gross HM, Soori GS, Hopkins JO, Fehrenbacher L, Sturtz K, Wozniak TF, Seay TE, Mamounas EP, Wolmark N. Primary results, NRG Oncology/NSABP B-35: A clinical trial of anastrozole vs tamoxifen in postmeno-pausal patients with DCIS undergoing lumpectomy plus radiotherapy. *Lancet*. 2015 Dec 10; online. PMID: 26686957. doi: [http://dx.doi.org/10.1016/S0140-6736\(15\)01168-x](http://dx.doi.org/10.1016/S0140-6736(15)01168-x).
6. Bear HD, Tang G, Rastogi P, Geyer CE, Liu Q, Robidoux A, Baez-Daiz L, Brufsky AM, Mehta RS, Fehrenbacher L, Young JA, Senecal FM, Gaur R, Margolese RG, Adams PT, Gross HM, Costantino JP, Paik S, Swain SW, Mamounas EP, Wolmark N. Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG oncology]): Secondary outcomes of a phase 3, randomised controlled trial. *Lancet Oncol*. 2015 Sep; 16 (9):1037-48. PMID: 26272770.
7. O'Sullivan CC, Bradbury I, Campbell C, Spielmann M, Perez EA, Joensuu H, Costantino JP, Delaloge S, Rastogi P, Zardavas D, Ballman KV, Holmes E, de Azambuja E, Piccart-Gebhart M, Zujewski JA, Gelber RD. Efficacy of adjuvant trastuzumab for patients with human epidermal growth factor receptor2-positive early breast cancer and tumors <= 2cm: A meta-analysis of the randomized trastuzumab trials. *Journal of Clinical Oncology*. 2015 Aug 20; 33 (24):2600-2608. PMID: 26101239. doi: 10.1200/JCO.2015.60.8620.
8. Chapman JW, Costantino JP, Dong B, Margolese RG, Pritchard KI, Shepherd LE, Gelmon KA, Wolmark N, Pollak MN. Octreotide LAR and tamoxifen versus tamoxifen in phase III randomize early breast cancer trials: NCIC CTG MA.14 and NSABP B-29. *Breast Cancer Res Treat*. 2015 Aug; 153 (2):353-60. PMID: 26276354.
9. Pogue-Geile KL, Song N, Jeong JH, Gavin PG, Kim SR, Blackmon NL, Finnigan M, Rastogi P, Fehrenbacher L, Mamounas EP, Swain SM, Wickerham DL, Geyer CE Jr, Costantino JP, Wolmark N, Paik S. Intrinsic Subtypes, PIK3CA Mutation, and the Degree of Benefit From Adjuvant Trastuzumab in the NSABP B-31 Trial. *Journal of Clinical Oncology : Official Journal of The American Society of Clinical Oncology*. 2015 Apr 20; 33 (12):1340-7. PMID: 25559813. doi: 10.1200/JCO.2014.56.2439.
10. Bergh J, Pritchard K, Albain K, Anderson S, Arriagada R, Barlow W, Bergström-Nordström W, ..., Costantino J, & others. Adjuvant bisphosphonate treatment in early breast cancer: Meta-analyses of individual patient data from randomised trials. *Lancet*. 2015; 386 (10001):1353-61. PMID: 26211824.
11. Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, Swain SM, Prowell T, Loibl S, Wickerham DL, Bogaerts J, Baselga J, Perou C, Blumenthal G, Blohmer J, Mamounas EP, Bergh J, Semiglazov V, Justice R, Eidtmann H, Paik S, Piccart M, Sridhara R, Fasching PA, Slaets L, Tang S, Gerber B, Geyer CE Jr, Pazdur R, Ditsch N, Rastogi P, Eiermann W, von Minckwitz G. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. *Lancet*. 2014 Jul 12; 384 (9938):164-72. PMID: 24529560. doi: 10.1016/S0140-6736(13)62422-8.
12. Land SR, Liu Q, Wickerham DL, Costantino JP, Ganz PA. Cigarette smoking, physical activity, and alcohol consumption as predictors of cancer incidence

- among women at high risk of breast cancer in the NSABP P-1 trial. *Cancer Epidemiol Biomarker Prev.* 2014 Feb; 23 (5):823-32. PMID: 24569437.
13. Klepin HD, Geiger AM, Bandos H, Costantino JP, Rapp SR, Sink KM, Lawrence JA, Atkinson HH, Espeland MA. Cognitive factors associated with adherence to oral antiestrogen therapy: Results from the Cognition in the Study of Tamoxifen and Raloxifene (Co-STAR) study. *Cancer Prev Res.* 2014 Jan; 7 (1):161-168. PMCID: PMC3924583. PMID: 24253314.
  14. Pogue-Geile KL, Kim C, Jeong JH, Tanaka N, Bandos H, Gavin PG, Fumagalli D, Goldstein LC, Sneige N, Burandt E, Taniyama Y, Bohn OL, Lee A, Kim SI, Reilly ML, Remillard MY, Blackmon NL, Kim SR, Horne ZD, Rastogi P, Fehrenbacher L, Romond EH, Swain SM, Mamounas EP, Wickerham DL, Geyer CE Jr, Costantino JP, Wolmark N, Paik S. Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31. *Journal of The National Cancer Institute.* 2013 Dec 4; 105 (23):1782-8. PMCID: PMC3848987. PMID: 24262440.
  15. Siziopikou KP, Anderson SJ, Cobleigh MA, Julian TB, Arthur DW, Zheng P, Mamounas EP, Pajon ER, Behrens RJ, Eakle JF, Leasure NC, Atkins JN, Polikoff JA, Seay TE, McCaskill-Stevens WJ, Rabinovitch R, Costantino JP, Wolmark N. Preliminary results of centralized HER2 testing in ductal carcinoma in situ (DCIS): NSABP B-43. *Breast Cancer Res Treat.* 2013 Nov 8; 142 (2):415-421. PMID: 24202240.
  16. Robidoux A, Tang G, Rastogi P, Geyer CE Jr, Azar CA, Atkins JN, Fehrenbacher L, Bear HD, Baez-Diaz L, Sarwar S, Margolese RG, Farrar WB, Brufsky AM, Shibata HR, Bandos H, Paik S, Costantino JP, Swain SM, Mamounas EP, Wolmark N. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. *The Lancet Oncology.* 2013 Nov; 14 (12):1183-92. PMID: 24095300.
  17. Swain SM, Tang G, Geyer CE, Rastogi P, Atkins JN, Donnellan PP, Fehrenbacher L, Azar CA, Robidoux A, Polikoff J, Brufsky A, Biggs DD, Levine EA, Zapa JL, Provencher L, Perez EA, Paik S, Costantino JP, Mamounas EP, Wolmark N. Definitive results of a phase 3, adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: The NSABP B-38 trial. *J Clin Oncol.* 2013 Sep; 31:3197-3204. PMID: 23940225.
  18. Ingle JN, Liu M, Wickerham DL, Schaid DJ, Wang L, Mushiroda T, Kubo M, Costantino JP, Vogel VG, Paik S, Ames MM, Jenkins GD, Batzler A, Carlson EE, Flockhart DA, Wolmark N, Nakamura Y, Weinshilboum RM. Selective estrogen receptor modulators and pharmacogenomic variation in ZNF423 regulation of BRCA1 expression: Individualized breast cancer prevention. *Cancer Discovery.* 2013 Jun 13; 3 (7):812-25. PMCID: 3710533. PMID: 23764426.
  19. Cuzick J, Sestak I, Bonanni B, Costantino JP, Cummings S, Decensi A, Dowsett M, Forbes JF, Ford L, Lacroix AZ, Mershon J, Mitlak BH, Powles T, Veronesi U, Vogel V, Wickerham DL, for the SERM Chemoprevention of Breast Cancer Overview Group. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. *Lancet.* 2013 May 25; 381:1827-34. PMID: 23639488.
  20. Kopec JA, Colangelo LH, Land SR, Julian TB, Brown AM, Anderson SJ, Krag DN, Ashikaga T, Costantino JP, Wolmark N, Ganz PA. Relationship between arm morbidity and patient-reported outcomes following surgery in women with node-

- negative breast cancer: NSABP Protocol B-32. *J Support Oncol.* 2013 Mar; 11 (1):22-30. PMID: 22951047.
21. Danhauer SC, Legault C, Bandos H, Kidwell K, Costantino J, Vaughan L, Avis NE, Rapp S, Coker LH, Naughton M, Naylor C, Terracciano A, Shumaker S. Positive and negative affect, depression, and cognitive processes in the Cognition in the Study of Tamoxifen and Raloxifene (Co-STAR) Trial. *Neuropsychology, development, and cognition. Section B, Aging, neuropsychology and cognition.* 2013; 20 (5):532-52. PMCID: 3815441. PMID: 23237718.
  22. Cecchini RS, Costantino JP, Cauley JA, Cronin WM, Wickerham DL, Bandos H, Weissfeld JL, Wolmark N. Baseline mammographic breast density and the risk of invasive breast cancer in postmenopausal women participating in the NSABP study of tamoxifen and raloxifene (STAR). *Cancer Prev Res (Phila).* 2012 Nov; 5 (11):1321-9. PMID: 23060039.
  23. Tang G, Kong Y, Chang C, Kong L, Costantino JP. Prediction of accrual closure date in multi-center clinical trials with discrete-time Poisson process models. *Pharm Stat.* 2012 Oct; 11 (5):351-6. PMID: 22411544.
  24. Paterson AH, Anderson SJ, Lembersky BC, Fehrenbacher L, Falkson CI, King KM, Weir LM, Brufsky AM, Dakhil S, Lad T, Baez-Diaz L, Gralow JR, Roubidoux A, Perez EA, Zheng P, Geyer Jr CE, Swain SM, Costantino JP, Mamounas EP, Wolmark N. Oral clondronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicenter, placebo-controlled, randomized trial. *Lancet Oncol.* 2012 Jul; 13:734-42. PMID: 22704583.
  25. Amir E, Cecchini RS, Ganz PA, Costantino JP, Beddows S, Hood N, Goodwin PJ. 25-Hydroxy vitamin-D, obesity, and associated variables as predictors of breast cancer risk and tamoxifen benefit in NSABP-P1. *Breast Cancer Res Treat.* 2012 Jun; 133 (3):1077-88. PMID: 22415479.
  26. Allred DC, Anderson SJ, Paik S, Wickerham DL, Nagtegaal ID, Swain SM, Mamounas EP, Julian TB, Geyer CE Jr, Costantino JP, Land SR, Wolmark N. Adjuvant Tamoxifen Reduces Subsequent Breast Cancer in Women With Estrogen Receptor-Positive Ductal Carcinoma in Situ: A Study Based on NSABP Protocol B-24. *J Clin Oncol.* 2012 Apr 2; 30 (12):1268-73. PMID: 22393101.
  27. Cecchini RS, Costantino JP, Cauley JA, Cronin WM, Wickerham DL, Land SR, Weissfeld JL, Wolmark N. Body mass index and the risk for developing invasive breast cancer among high-risk women in NSABP P-1 and STAR breast cancer prevention trials. *Cancer Prev Res (Phila).* 2012 Apr; 5 (4):583-92. PMID: 22318751.
  28. Bear HD, Tang G, Rastogi P, Geyer CE Jr, Roubidoux A, Atkins JN, Baez-Diaz L, Brufsky AM, Mehta RS, Fehrenbacher L, Young JA, Senecal FM, Gaur R, Margolese RG, Adams PT, Gross HM, Costantino JP, Swain SM, Mamounas EP, Wolmark N. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. *N Engl J Med.* 2012 Jan 26; 366 (4):310-20. PMCID: PMC3401076. PMID: 22276821.
  29. Schaid DJ, Sinnwell JP, Jenkins GD, McDonnell SK, Ingle JN, Kubo M, Goss PE, Costantino JP, Wickerham DL, Weinshilboum RM. Using the gene ontology to scan multilevel gene sets for associations in genome wide association studies. *Genetic Epidemiol.* 2012 Jan; 36:3-16. PMID: 22161999.

30. Runowicz CD, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Ford LG, Vogel VG, Wolmark N. Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR). *Am J Obst Gynecol*. 2011 Dec; 205 (6):535.e1-5. PMID: 21872200.
31. Tang G, Cuzick J, Costantino JP, Dowsett M, Forbes JF, Cragger M, Mamounas EP, Shak S, Wolmark N. Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: recurrence score alone and integrated with pathologic and clinical factors. *J Clin Oncol*. 2011 Nov 20; 29 (33):4365-72. PMCID: PMC3221521. PMID: 22010013.
32. Kim C, Tang G, Pogue-Geile KL, Costantino JP, Baehner FL, Baker J, Cronin MT, Watson D, Shak S, Bohn OL, Fumagalli D, Taniyama Y, Lee A, Reilly ML, Vogel VG, McCaskill-Stevens W, Ford LG, Geyer CE Jr, Wickerham DL, Wolmark N, Paik S. Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer. *J Clin Oncol*. 2011 Nov 1; 29 (31):4160-7. PMCID: PMC3208536. PMID: 21947828.
33. Goetz MP, Schaid DJ, Wickerham DL, Safgren S, Mushiroda T, Kubo M, Batzler A, Costantino JP, Vogel VG, Paik S, Carlson EE, Flockhart DA, Wolmark N, Nakamura Y, Weinshilboum RM, Ingle JN, Ames MM. Evaluation of CYP2D6 and efficacy of tamoxifen and raloxifene in women treated for breast cancer chemoprevention: results from the NSABP P1 and P2 clinical trials. *Clin Cancer Res*. 2011 Nov 1; 17 (21):6944-51. PMCID: PMC3207003. PMID: 21880792.
34. Land SR, Cronin WM, Wickerham DL, Costantino JP, Christian NJ, Klein WM, Ganz PA. Cigarette smoking, obesity, physical activity, and alcohol use as predictors of chemoprevention adherence in the National Surgical Adjuvant Breast and Bowel Project P-1 Breast Cancer Prevention Trial. *Cancer Prev Res (Phila)*. 2011 Sep; 4 (9):1393-400. PMCID: PMC3180877. PMID: 21862698.
35. Matsuno RK, Costantino JP, Ziegler RG, Anderson GL, Li H, Pee D, Gail MH. Projecting individualized absolute invasive breast cancer risk in Asian and Pacific Islander American women. *J Natl Cancer Inst*. 2011 Jun 22; 103 (12):951-61. PMCID: PMC3119648. PMID: 21562243.
36. Freedman AN, Yu B, Gail MH, Costantino JP, Graubard BI, Vogel VG, Anderson GL, McCaskill-Stevens W. Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older. *J Clin Oncol*. 2011 Jun 10; 29 (17):2327-33. PMCID: PMC3107748. PMID: 21537036.
37. Tang G, Shak S, Paik S, Anderson SJ, Costantino JP, Geyer CE Jr, Mamounas EP, Wickerham DL, Wolmark N. Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20. *Breast Cancer Res Treat*. 2011 May; 127 (1):133-142. PMID: 21221771.
38. Ganz PA, Land SR, Geyer CE Jr, Cecchini RS, Costantino JP, Pajon ER, Fehrenbacher L, Atkins JN, Polikoff JA, Vogel VG, Erban JK, Livingston RB, Perez EA, Mamounas EP, Wolmark N, Swain SM. Menstrual History and Quality-of-Life Outcomes in Women With Node-Positive Breast Cancer Treated With Adjuvant Therapy on the NSABP B-30 Trial. *J Clin Oncol*. 2011 Mar 20; 29 (9):1110-6. PMID: 21300930.

39. Wapnir IL, Dignam JJ, Fisher B, Mamounas EP, Anderson SJ, Julian TB, Land SR, Margolese RG, Swain SM, Costantino JP, Wolmark N. Long-Term Outcomes of Invasive Ipsilateral Breast Tumor Recurrences After Lumpectomy in NSABP B-17 and B-24 Randomized Clinical Trials for DCIS. *J Natl Cancer Inst.* 2011 Mar 16; 103 (6):478-88. PMID: 21398619.
40. Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, Cutter D, Davies C, ....., Costantino J, & others. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: Meta-analysis of individual patient data for 10 801 women in 17 randomised trials. *Lancet.* 2011; 378 (9804):1707-16. PMID: 22019144.
41. Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Costantino JP, Ashikaga T, Weaver DL, Mamounas EP, Jalovec LM, Frazier TG, Noyes RD, Robidoux A, Scarth HM, Wolmark N. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. *Lancet Oncol.* 2010 Oct; 11 (10):927-33. PMCID: PMC3041644. PMID: 20863759.
42. Land SR, Kopec JA, Julian TB, Brown AM, Anderson SJ, Krag DN, Christian NJ, Costantino JP, Wolmark N, Ganz PA. Patient-reported outcomes in sentinel node-negative adjuvant breast cancer patients receiving sentinel-node biopsy or axillary dissection: National Surgical Adjuvant Breast and Bowel Project phase III protocol B-32. *J Clin Oncol.* 2010 Sep 1; 28 (25):3929-36. PMCID: PMC2940391. PMID: 20679600.
43. Ashikaga T, Krag DN, Land SR, Julian TB, Anderson SJ, Brown AM, Skelly JM, Harlow SP, Weaver DL, Mamounas EP, Costantino JP, Wolmark N, National Surgical Adjuvant Breast, Bowel Project. Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection. *J Surg Oncol.* 2010 Aug 1; 102 (2):111-8. PMCID: PMC3072246. PMID: 20648579.
44. Yang SX, Costantino JP, Kim C, Mamounas EP, Nguyen D, Jeong JH, Wolmark N, Kidwell K, Paik S, Swain SM. Akt phosphorylation at Ser473 predicts benefit of paclitaxel chemotherapy in node-positive breast cancer. *J Clin Oncol.* 2010 Jun 20; 28 (18):2974-81. PMCID: PMC2903333. PMID: 20479407.
45. Swain SM, Jeong JH, Geyer CE Jr, Costantino JP, Pajon ER, Fehrenbacher L, Atkins JN, Polikoff J, Vogel VG, Erban JK, Rastogi P, Livingston RB, Perez EA, Mamounas EP, Land SR, Ganz PA, Wolmark N. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. *N Engl J Med.* 2010 Jun 3; 362 (22):2053-65. PMCID: PMC2935316. PMID: 20519679.
46. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER, Wade JL 3rd, Robidoux A, Margolese RG, James J, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N, National Surgical Adjuvant Breast and Bowel Project. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer. *Cancer Prev Res (Phila).* 2010 Jun; 3 (6):696-706. PMCID: PMC2935331. PMID: 20404000.
47. Mamounas EP, Tang G, Fisher B, Paik S, Shak S, Costantino JP, Watson D, Geyer CE Jr, Wickerham DL, Wolmark N. Association between the 21-gene

- recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. *J Clin Oncol*. 2010 Apr 1; 28 (10):1677-83. PMCID: PMC2849763. PMID: 20065188.
48. Wilkinson NW, Yothers G, Lopa S, Costantino JP, Petrelli NJ, Wolmark N. Long-term survival results of surgery alone versus surgery plus 5-fluorouracil and leucovorin for stage II and stage III colon cancer: Pooled analysis of NSABP C-01 through C-05. Baseline from which to compare modern adjuvant trials. *Ann Surg Oncol*. 2010; 17 (4):959-966. PMCID: PMC2935319. PMID: 20082144.
  49. Eng-Wong J, Costantino JP, Swain SM. The impact of systemic therapy following ductal carcinoma in situ. *Journal of the National Cancer Institute. Monographs*. 2010; 2010 (41):200-3. PMID: 20956830 (invited).
  50. Vogel VG, Costantino JP, Wickerham DL, McCaskill-Stevens W, Clarfeld RB, Grant MD, Wolmark N. Carcinoma in situ outcomes in National Surgical Adjuvant Breast and Bowel Project Breast Cancer Chemoprevention Trials. *Journal of the National Cancer Institute. Monographs*. 2010; 2010 (41):181-6. PMID: 20956826 (invited).
  51. Dunn BK, Greene MH, Kelley JM, Costantino JP, Clifford RJ, Hu Y, Tang G, Kazerouni N, Rosenberg PS, Meerzaman DM, Buetow KH. Novel pathway analysis of genomic polymorphism-cancer risk interaction in the Breast Cancer Prevention Trial. *Internat J Molecul Epid Genet*. 2010; 1 (4):332-49. PMCID: PMC2998292. PMID: 21152245.
  52. Anderson SJ, Wapnir I, Dignam JJ, Fisher B, Mamounas EP, Jeong JH, Geyer CE Jr, Wickerham DL, Costantino JP, Wolmark N. Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer. *J Clin Oncol*. 2009 May 20; 27 (15):2466-73. PMCID: PMC2684852. PMID: 19349544.
  53. Kramer BS, Haggerty KL, Justman S, Somerfield MR, Albertsen PC, Blot WJ, Carter HB, Costantino JP, Epstein JI, Godley PA, Harria RP, Wilt TJ, Wittes J, Zon R, Schellhammer P. Use of 5alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. *J Urol*. 2009 Apr; 181 (4):1642-57. PMID: 19249063 (invited).
  54. Swain SM, Land SR, Ritter MW, Costantino JP, Cecchini RS, Mamounas EP, Wolmark N, Ganz PA. Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trial. *Breast Cancer Res Treat*. 2009 Jan; 113 (2):315-20. PMID: 18302020.
  55. Wickerham DL, Costantino JP, Vogel VG, Cronin WM, Cecchini RS, Ford LG, Wolmark N. The use of tamoxifen and raloxifene for the prevention of breast cancer. *Recent Results Cancer Res. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer*. 2009; 181:113-9. PMID: 19213563 (invited).
  56. Ross DT, Kim CY, Tang G, Bohn OL, Beck RA, Ring BZ, Seitz RS, Paik S, Costantino JP, Wolmark N. Chemosensitivity and stratification by a five monoclonal antibody immunohistochemistry test in the NSABP B14 and B20 trials. *Clin Cancer Res*. 2008 Oct 15; 14 (20):6602-9. PMCID: PMC2722068. PMID: 18927301.

57. Shen Y, Costantino JP, Qin J. Tamoxifen chemoprevention treatment and time to first diagnosis of estrogen receptor-negative breast cancer. *J Natl Cancer Inst.* 2008 Oct 15; 100 (20):1448-53. PMID: 18840821.
58. Wickerham DL, O'Connell MJ, Costantino JP, Cronin WM, Paik S, Geyer CE Jr, Ganz PA, Petrelli N, Mamounas EP, Julian TB, Wolmark N. The half century of clinical trials of the National Surgical Adjuvant Breast And Bowel Project. *Seminars Oncol.* 2008 Oct; 35 (5):522-9. PMID: 18929150.
59. Wapnir IL, Aebi S, Geyer CE, Zahrieh D, Gelber RD, Anderson SJ, Robidoux A, Bernhard J, Maibach R, Castiglione-Gertsch M, Coates AS, Piccart MJ, Clemons MJ, Costantino JP, Wolmark N, IBCSG, BIG, NSABP. A randomized clinical trial of adjuvant chemotherapy for radically resected locoregional relapse of breast cancer: IBCSG 27-02, BIG 1-02, and NSABP B-37. *Clin Breast Cancer.* 2008 Jun; 8 (3):287-92. PMID: 18650162.
60. Cella D, Land SR, Chang CH, Day R, Costantino JP, Wolmark N, Ganz PA. Symptom measurement in the Breast Cancer Prevention Trial (BCPT) (P-1): psychometric properties of a new measure of symptoms for midlife women. *Breast Cancer Res Treat.* 2008 Jun; 109 (3):515-26. PMID: 17851765.
61. Mamounas EP, Jeong JH, Wickerham DL, Smith RE, Ganz PA, Land SR, Eisen A, Fehrenbacher L, Farrar WB, Atkins JN, Pajon ER, Vogel VG, Kroener JF, Hutchins LF, Robidoux A, Hoehn JL, Ingle JN, Geyer CE Jr, Costantino JP, Wolmark N. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial. *J Clin Oncol.* 2008 Apr 20; 26 (12):1965-71. PMID: 18332472.
62. Jeong JH, Jung SH, Costantino JP. Nonparametric inference on median residual life function. *Biometrics.* 2008 Mar; 64 (1):157-63. PMID: 17501936.
63. Gail MH, Costantino JP, Pee D, Bondy M, Newman L, Selvan M, Anderson GL, Malone KE, Marchbanks PA, McCaskill-Stevens W, Norman SA, Simon MS, Spirtas R, Ursin G, Bernstein L. Projecting individualized absolute invasive breast cancer risk in African American women. *J Natl Cancer Inst.* 2007 Dec 5; 99 (23):1782-92. PMID: 18042936.
64. Shen Y, Qin J, Costantino JP. Inference of Tamoxifen's Effects on Prevention of Breast Cancer from a Randomized Controlled Trial. *J Amer Stat Assoc.* 2007 Dec 1; 102 (480):1235-1244. PMID: 19662105.
65. Land SR, Ritter MW, Costantino JP, Julian TB, Cronin WM, Haile SR, Wolmark N, Ganz PA. Compliance with patient-reported outcomes in multicenter clinical trials: methodologic and practical approaches. *J Clin Oncol.* 2007 Nov 10; 25 (32):5113-20. PMID: 17991930.
66. Fisher ER, Costantino JP, Leon ME, Bandos H, Palekar AS, Fisher B, Wolmark N. Pathobiology of small invasive breast cancers without metastases (T1a/b, N0, M0): National Surgical Adjuvant Breast and Bowel Project (NSABP) protocol B-21. *Cancer.* 2007 Nov 1; 110 (9):1929-36. PMID: 17896781.
67. Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Ashikaga T, Weaver DL, Miller BJ, Jalovec LM, Frazier TG, Noyes RD, Robidoux A, Scarth HM, Mammolito DM, McCready DR, Mamounas EP, Costantino JP, Wolmark N, National Surgical Adjuvant Breast and Bowel Project. Technical outcomes of

- sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. *Lancet Oncol.* 2007 Oct; 8 (10):881-8. PMID: 17851130.
68. Julian TB, Land SR, Fourchotte V, Haile SR, Fisher ER, Mamounas EP, Costantino JP, Wolmark N. Is sentinel node biopsy necessary in conservatively treated DCIS? *Ann Surg Oncol.* 2007 Aug; 14 (8):2202-8. PMID: 17534687.
  69. Fisher ER, Land SR, Saad RS, Fisher B, Wickerham DL, Wang M, Costantino JP, Wolmark N. Pathologic variables predictive of breast events in patients with ductal carcinoma in situ. *Am J Clin Pathol.* 2007 Jul; 128 (1):86-91. PMID: 17580274.
  70. Land SR, Kopec JA, Cecchini RS, Ganz PA, Wieand HS, Colangelo LH, Murphy K, Kuebler JP, Seay TE, Needles BM, Bearden JD 3rd, Colman LK, Lanier KS, Pajon ER Jr, Cella D, Smith RE, O'Connell MJ, Costantino JP, Wolmark N. Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. *J Clin Oncol.* 2007 Jun 1; 25 (16):2205-11. PMID: 17470850.
  71. Hudis CA, Barlow WE, Costantino JP, Gray RJ, Pritchard KI, Chapman JA, Sparano JA, Hunsberger S, Enos RA, Gelber RD, Zujewski JA. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. *J Clin Oncol.* 2007 May 20; 25 (15):2127-32. PMID: 17513820.
  72. Mamounas EP, Lembersky B, Jeong JH, Cronin W, Harkins B, Geyer C, Wickerham DL, Paik S, Costantino J, Wolmark N. NSABP B-42: a clinical trial to determine the efficacy of five years of letrozole compared with placebo in patients completing five years of hormonal therapy consisting of an aromatase inhibitor (AI) or tamoxifen followed by an AI in prolonging disease. *Clinical Breast Cancer.* 2006 Dec; 7 (5):416-21. PMID: 17239269. doi: 10.3816/CBC.2006.n.061.
  73. Taghian AG, Jeong JH, Mamounas EP, Parda DS, Deutsch M, Costantino JP, Wolmark N. Low locoregional recurrence rate among node-negative breast cancer patients with tumors 5 cm or larger treated by mastectomy, with or without adjuvant systemic therapy and without radiotherapy: results from five national surgical adjuvant breast and. *J Clin Oncol.* 2006 Aug 20; 24 (24):3927-32. PMID: 16921044.
  74. Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, Cronin M, Baehner FL, Watson D, Bryant J, Costantino JP, Geyer CE Jr, Wickerham DL, Wolmark N. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. *J Clin Oncol.* 2006 Aug 10; 24 (23):3726-34. PMID: 16720680.
  75. Abramson N, Costantino JP, Garber JE, Berliner N, Wickerham DL, Wolmark N. Effect of Factor V Leiden and prothrombin G20210-->A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial. *J Natl Cancer Inst.* 2006 Jul 5; 98 (13):904-10. PMID: 16818854.
  76. Wickerham DL, Costantino JP, Mamounas EP, Julian TB. The landmark surgical trials of the National Surgical Adjuvant Breast and Bowel Project. *World J Surg.* 2006 Jul; 30 (7):1138-46. PMID: 16794909 (invited).

77. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon ER Jr, Wade JL 3rd, Robidoux A, Margolese RG, James J, Lippman SM, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N, National Surgical Adjuvant Breast and Bowel Project (NSABP). Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. *JAMA*. 2006 Jun 21; 295 (23):2727-41. PMID: 16754727.
78. Land SR, Wickerham DL, Costantino JP, Ritter MW, Vogel VG, Lee M, Pajon ER, Wade JL 3rd, Dakhil S, Lockhart JB Jr, Wolmark N, Ganz PA. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. *JAMA*. 2006 Jun 21; 295 (23):2742-51. PMID: 16754728.
79. Beattie MS, Costantino JP, Cummings SR, Wickerham DL, Vogel VG, Dowsett M, Folklerd EJ, Willett WC, Wolmark N, Hankinson SE. Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1). *J Natl Cancer Inst*. 2006 Jan 18; 98 (2):110-5. PMID: 16418513.
80. El-Saed A, Kuller L, Newman A, Lopez O, Costantino JP, Mctigue K, Cushman M, Kronmal R. Geographic variations in stroke incidence and mortality among older populations in four U.S. communities. *Stroke*. 2006; 37 (8):1975-79. PMID: 16794205.
81. El-Saed A, Kuller L, Newman A, Lopez O, Costantino JP, Mctigue K, Cushman M, Kronmal R. Factors associated with geographic variations in stroke incidence among older populations in four US communities. *Stroke*. 2006; 37 (8):1980-85. PMID: 16794204.
82. Jeong JH, Costantino JP. Application of smoothing methods to evaluate treatment-prognostic factor interactions in breast cancer data. *Cancer Invest*. 2006; 24 (3):288-93. PMID: 16809157.
83. Modugno F, Ngo DL, Allen GO, Kuller LH, Vogel VG, Ness RB, Costantino JP, Cauley JA. Breast cancer risk factors and mammographic breast density in women over age 70. *Breast Cancer Res Treat*. 2006; 97 (2):157-66. PMID: 16362132.
84. Kopec JA, Land SR, Cecchini RS, Ganz PA, Cella D, Costantino JP, Wieand HS, Smith RE, Kuebler JP, Wolmark N. Validation of a Self-Reported Neurotoxicity Scale in Patients with Operable Colon Cancer Receiving Oxaliplatin. *J Support Oncol*. 2006; 4 (8):W1-W8.
85. Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, Bevers TB, Kavanah MT, Atkins JN, Margolese RG, Runowicz CD, James JM, Ford LG, Wolmark N. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. *J Natl Cancer Inst*. 2005 Nov 16; 97 (22):1652-62. PMID: 16288118.
86. Gorin MB, Costantino JP, Kulacoglu DN, Demirci FY, Wickerham DL, Fisher B, Wolmark N. Is tamoxifen a risk factor for retinal vaso-occlusive disease? *Retina*. 2005 Jun; 25 (4):523-6. PMID: 15933605.
87. Chalas E, Costantino JP, Wickerham DL, Wolmark N, Lewis GC, Bergman C, Runowicz CD. Benign gynecologic conditions among participants in the Breast

- Cancer Prevention Trial. *Am J Obstet Gynecol*. 2005 Apr; 192 (4):1230-7; discussion 1237-9. PMID: 15846210.
88. Abe O, Abe R, Enomoto K, Kikuchi K, Koyama H, Masuda H, Nomura Y, Sakai K, ....., Costantino J, & others. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials. *Lancet*. 2005; 366 (9503):2087-106. PMID: 1630786.
  89. Wang J, Costantino JP, Tan-Chiu E, Wickerham DL, Paik S, Wolmark N. Lower-category benign breast disease and the risk of invasive breast cancer. *J Natl Cancer Inst*. 2004 Apr 21; 96 (8):616-20. PMID: 15100339.
  90. Agatisa PK, Ness RB, Roberts JM, Costantino JP, Kuller LH, McLaughlin MK. Impairment of endothelial function in women with a history of preeclampsia: an indicator of cardiovascular risk. *Am J Physiol Heart Circ Physiol*. 2004 Apr; 286 (4):H1389-93. PMID: 15020302.
  91. Martino S, Costantino JP, McNabb M, Mershon J, Bryant JL, Powles T, Secret RJ. The role of selective estrogen receptor modulators in the prevention of breast cancer: comparison of the clinical trials. *Oncologist*. 2004; 9 (2):116-125. PMID: 15047916.
  92. Wang HE, Kupas DF, Paris PM, Bates RR, Costantino JP, Yealy DM. Multivariate predictors of failed prehospital endotracheal intubation. *Acad Emerg Med*. 2003 Jul; 10 (7):717-24. PMID: 12837645.
  93. Tan-Chiu E, Wang J, Costantino JP, Paik S, Butch C, Wickerham DL, Fisher B, Wolmark N. Effects of tamoxifen on benign breast disease in women at high risk for breast cancer. *J Natl Cancer Inst*. 2003 Feb 19; 95 (4):302-7. PMID: 12591986.
  94. Vogel VG, Costantino JP, Wickerham DL, Cronin WM. National surgical adjuvant breast and bowel project update: prevention trials and endocrine therapy of ductal carcinoma in situ. *Clin Cancer Res*. 2003 Jan; 9 (1):495S-501S. PMID: 12538506.
  95. Cushman M, Costantino JP, Bovill EG, Wickerham DL, Buckley L, Roberts JD, Krag DN. Effect of tamoxifen on venous thrombosis risk factors in women without cancer: the Breast Cancer Prevention Trial. *Br J Haematol*. 2003 Jan; 120 (1):109-16. PMID: 12492585.
  96. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Wolmark N. The study of tamoxifen and raloxifene: preliminary enrollment data from a randomized breast cancer risk reduction trial. *Clin Breast Cancer*. 2002 Jun; 3 (2):153-9. PMID: 12123540.
  97. Wickerham DL, Fisher B, Wolmark N, Bryant JL, Costantino JP, Bernstein L, Runowicz CD. Association of tamoxifen and uterine sarcoma. *J Clin Oncol*. 2002; 20 (11):2758-60. PMID: 12039943.
  98. Costantino J. The impact of hormonal treatments on quality of life of patients with metastatic breast cancer. *Clinical Therapeutics*. 2002; 24:C26-42. PMID: 12117073.
  99. Dunn BK, Anthony M, Sherman S, Costantino JP. Conclusions: Considerations regarding SERMs. *Annals of The New York Academy of Sciences*. 2001 Dec; 949:352-65. PMID: 11795376.

100. Costantino JP. Benefit/risk assessment of SERM therapy: clinical trial versus clinical practice settings. *Annals of The New York Academy of Sciences*. 2001 Dec; 949:280-5. PMID: 11795363.
101. Day R, Ganz PA, Costantino JP. Tamoxifen and depression: more evidence from the National Surgical Adjuvant Breast and Bowel Project's Breast Cancer Prevention (P-1) Randomized Study. *J Natl Cancer Inst*. 2001 Nov 7; 93 (21):1615-23. PMID: 11698565.
102. Costantino JP, Vogel VG. Results and implications of the Royal Marsden and other tamoxifen chemoprevention trials: an alternative view. *Clin Breast Cancer*. 2001 Apr; 2 (1):41-6. PMID: 11899381.
103. Gail MH, Costantino JP. Validating and improving models for projecting the absolute risk of breast cancer. *J Natl Cancer Inst*. 2001 Mar 7; 93 (5):334-5. PMID: 11238688.
104. Cushman M, Costantino JP, Tracy RP, Song K, Buckley L, Roberts JD, Krag DN. Tamoxifen and cardiac risk factors in healthy women: Suggestion of an anti-inflammatory effect. *Arterioscler Thromb Vasc Biol*. 2001 Feb; 21 (2):255-61. PMID: 11156862.
105. Reis SE, Costantino JP, Wickerham DL, Tan-Chiu E, Wang J, Kavanah M. Cardiovascular effects of tamoxifen in women with and without heart disease: breast cancer prevention trial. National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial Investigators. *J Natl Cancer Inst*. 2001 Jan 3; 93 (1):16-21. PMID: 11136837.
106. Phillips ML, Esmen NA, Costantino J. The reliability of multiple regression and an alternative method for extracting task-specific exposure estimates from time-weighted average data. *Applied Occupational and Environmental Hygiene*. 2001 Jan; 16 (1):56-65. PMID: 11202029. doi: 10.1080/104732201456131.
107. Costantino JP, Vogel VG, Wickerham DL. Reducing the risk of breast cancer: Balancing the risk-benefit analogies. *Prev Care Cancer*. 2001; 21 (9):13-21.
108. King M, Wieand HS, Hale K, Lee M, Walsh T, Owens K, Tait J, Ford L, Costantino JP, Wickerham DL, Wolmark N, Fisher B. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. *JAMA*. 2001; 286 (18):2251-2256. PMID: 11710890.
109. Martin TJ, Hovis JD, Costantino JP, Bierman MI, Donahoe MP, Rogers RM, Kreit JW, Sciruba FC, Stiller RA, Sanders MH. A randomized, prospective evaluation of noninvasive ventilation for acute respiratory failure. *Am J Respir Crit Care Med*. 2000 Mar; 161:807-13. PMID: 10712326.
110. Sanders MH, Costantino JP, Strollo PJ, Strunicki K, Atwood CW. The impact of split-night polysomnography for diagnosis and positive pressure therapy titration on treatment acceptance and adherence in sleep apnea/hypopnea. *Sleep*. 2000; 23 (1):17-24. PMID: 10678462.
111. Gail MH, Costantino JP, Bryant J, Croyle R, Freedman L, Helzlsouer K, Vogel V. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. *J Natl Cancer Inst*. 1999 Nov 3; 91 (21):1829-46. PMID: 10547390.
112. Costantino JP, Gail MH, Pee D, Anderson S, Redmond CK, Benichou J, Wieand HS. Validation studies for models projecting the risk of invasive and total breast

- cancer incidence. *J Natl Cancer Inst.* 1999 Sep 15; 91 (18):1541-8. PMID: 10491430.
113. Day R, Ganz PA, Costantino JP, Cronin WM, Wickerham DL, Fisher B. Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. *J Clin Oncol.* 1999 Sep; 17 (9):2659-69. PMID: 10561339.
  114. Fisher E, Dignam J, Tan Chiu E, Costantino JP, Fisher B, Paik S, Wolmark N. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17: intraductal carcinoma. *Cancer.* 1999 Aug; 86 (3):429-38. PMID: 10430251.
  115. Arena VC, Costantino JP, Sussman NB, Redmond CK. Issues and findings in the evaluation of occupational risk among women high nickel alloys workers. *Am J Ind Med.* 1999 Jul; 36 (1):114-21. PMID: 10361595.
  116. Arena VC, Sussman NB, Redmond CK, Costantino JP, Trauth JM. Using alternative comparison populations to assess occupation-related mortality risk. Results for the high nickel alloys workers cohort. *J Occup Environ Med.* 1998 Oct; 40 (10):907-16. PMID: 9800177.
  117. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. *J Natl Cancer Inst.* 1998 Sep 16; 90 (18):1371-88. PMID: 9747868.
  118. Smith AT, Kuller LH, Perper JA, Brent DA, Moritz G, Costantino JP. The epidemiology of homicide in Allegheny County, Pennsylvania between 1966-1974 and 1984-1993. *Prev Med.* 1998 Jun; 27:452-60. PMID: 9612836.
  119. Ganz P, Day R, Costantino JP. Compliance with quality of life data collection in the National Surgical Adjuvant Breast and Bowel Project (NSABP) Breast Cancer Prevention Trial. *Stat Med.* 1998 Apr; 17:613-622. PMID: 9549810.
  120. Gorin MB, Day R, Costantino JP, Fisher B, Redmond CK, Wickerham L, Gomolin JE, Margolese RG, Mathen MK, Bowman DM, Kaufman DI, Dimitrov NV, Singerman LJ, Bornstein R, Wolmark N, Kaufmann D. Long-term tamoxifen citrate use and potential ocular toxicity. *Am J Ophthalmol.* 1998 Apr; 125 (4):493-501. PMID: 9559735.
  121. Fisher B, Dignam J, Wolmark N, Mamounas E, Costantino JP. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. *J Clin Oncol.* 1998 Feb; 16 (2):441-452. PMID: 9469327.
  122. Bryant J, Fisher B, Gündüz N, Costantino JP, Emir B. S-phase fraction combined with other patient and tumor characteristics for the prognosis of node-negative, estrogen-receptor-positive breast cancer. *Breast Cancer Res Treat.* 1998; 51 (3):239-53. PMID: 10068082.
  123. Abe O, Abe R, Enomoto K, Kikuchi K, Koyama H, Nomura Y, Sakai K, Sugimachi K, ....., Costantino J, & others. Tamoxifen for early breast cancer: An overview of the randomised trials. *Lancet.* 1998; 351 (9114):1451-67. PMID: 9605801.
  124. Massoudi MS, Meilahan EN, Orchard TJ, Foley TP, Kuller LH, Costantino JP, Buhari AM. Thyroid function and perimenopausal lipid and weight changes:

- the Thyroid Study in Healthy Women (TSH-W). *J Womens Health*. 1997 Oct; 6 (5):553-8. PMID: 9356978.
125. Costantino JP, Kuller LH, Ives DG, Fisher B, Dignam J. Coronary heart disease mortality and adjuvant tamoxifen therapy. *J Natl Cancer Inst*. 1997 Jun 4; 89 (11):776-82. PMID: 9182975.
  126. Dignam JD, Redmond CK, Fisher BF, Costantino JP, Edwards BK. Prognosis among African-American women and white women with lymph node negative breast carcinoma: findings from two randomized clinical trials of the National Surgical Adjuvant Breast and Bowel Project (NSABP). *Cancer*. 1997 Jun; 80 (1):80-90. PMID: 9210712.
  127. Fisher B, Costantino JP. Highlights of the NSABP Breast Cancer Prevention Trial. *Cancer Control*. 1997 Jan; 4 (1):78-86. PMID: 10763006.
  128. Strollo PJ Jr, Sanders MH, Costantino JP, Walsh SK, Stiller RA, Atwood CW Jr. Split-night studies for the diagnosis and treatment of sleep-disordered breathing. *Sleep*. 1996 Dec; 19:S255-9. PMID: 9085525.
  129. Redmond CK, Costantino JP, Anderson SJ, Yu K. Statistical concepts and biomedical research. *Urol Oncol*. 1996 Dec; 2 (6):166-170. PMID: 21224164.
  130. Lazebnik N, Hill LM, Costantino JP, Many A, Martin JG. Vibroacoustic stimulation enhances visualization of the four-chamber cardiac view in the third trimester. *Ultrasound Obstet Gynecol*. 1996 Nov; 8 (5):309-13. PMID: 8978002.
  131. Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham DL, Wolmark N, Costantino JP, Redmond C, Fisher ER, Bowman DM, Deschenes L, Dimitrov NV, Margolese RG, Robidoux A, Shibata H, Terz J, Paterson AH, Feldman MI, Farrar W, Evans J, Lickley HL. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. *J Natl Cancer Inst*. 1996 Nov; 88 (21):1529-42. PMID: 8901851.
  132. Fisher ER, Costantino JP, Fisher B, Palekar SM, Suarez CM, Wolmark N. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) Protocol B-17. Five-year observations concerning lobular carcinoma in situ. *Cancer*. 1996 Oct; 78 (7):1403-16. PMID: 8839545.
  133. Fisher B, Dignam J, Mamounas EP, Costantino JP, Wickerham DL, Redmond C, Wolmark N, Dimitrov NV, Bowman DM, Glass AG, Atkins JN, Abramson N, Sutherland CM, Aron BS, Margolese RG. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of f. *J Clin Oncol*. 1996 Jul; 14 (7):1982-92. PMID: 8683228.
  134. Redmond CK, Costantino JP. Design and current status of the NSABP breast cancer prevention trial. *Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progrès Dans Les Recherches Sur Le Cancer*. 1996; 140:309-17. PMID: 8787073.
  135. Anderson SJ, Costantino JP, Brown AM, Bryant JL, Cronin WM, Dignam JJ, Jones JM, Rockette H. Breast cancer trials on trial: a case of conflicting ethical interests. *Cancer*. 1995 Oct 1; 76 (7):1294-5. PMID: 8630911.
  136. Massoudi MS, Meilahn EN, Orchard TJ, Foley TP, Kuller LH, Costantino JP. Prevalence of thyroid antibodies among healthy middle-aged women.

- Findings from the thyroid study in healthy women. *Ann Epidemiol.* 1995 May; 5 (3):229-233. PMID: 7606312.
137. Costantino JP, Redmond CK, Bearden A. Occupationally related cancer risk among coke oven workers: 30 years of follow-up. *J Occup Environ Med.* 1995 May; 37 (5):597-604. PMID: 7640988.
  138. Fisher ER, Costantino JP, Fisher B, Palekar AS, Redmond C. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) Protocol B-17. Intraductal carcinoma (ductal carcinoma in situ). The National Surgical Adjuvant Breast and Bowel Project Collaborating Investigators. *Cancer.* 1995 Mar; 75 (6):1310-1319. PMID: 7882281.
  139. Fisher ER, Costantino JP, Fisher B, Palekar AS, Mamounas E. Blunting the counterpoint. *Cancer.* 1995; 75:1224-1227.
  140. Sanders MH, Kern NB, Costantino JP, Stiller RA, Strollo PJ Jr, Studnicki KA, Coates JA, Richards TJ. Accuracy of end-tidal and transcutaneous PCO2 monitoring during sleep. *Chest.* 1994 Aug; 106 (2):472-83. PMID: 7774323.
  141. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. *Journal of the National Cancer Institute.* 1994 Apr; 86 (7):527-37. PMID: 8133536.
  142. Slesinski MJ, Gloninger MF, Costantino JP, Orenstein DM. Lipid levels in adults with cystic fibrosis. *J Am Diet Assoc.* 1994 Apr; 94 (4):402-8. PMID: 8144807.
  143. Fisher ER, Costantino JP. Quality assurance of pathology in clinical trials. The National Surgical Adjuvant Breast and Bowel Project experience. *Cancer.* 1994; 74:2638-41. PMID: 7954278.
  144. Fisher ER, Palekar AS, Stoner F, Costantino JP. Mucocele-like lesions and mucinous carcinoma of breast. *Internat J Surg Path.* 1994; 4:213-220.
  145. Sanders MH, Kern NB, Costantino JP, Stiller RA, Studnicki K, Coates J, Orris S, Schirmerman S. Prescription of positive airway pressure for sleep apnea on the basis of a partial-night trial. *Sleep.* 1993 Dec; 16 (8):S106-7. PMID: 8177993.
  146. Fisher B, Costantino JP, Redmond CK, Fisher ER, Margolese R. Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. *N Engl J Med.* 1993 Jun; 328 (22):1581-1586. PMID: 8292119.
  147. Sanders MH, Kern NB, Costantino JP, Stiller RA, Studnicki K, Coates J, Orris S, Schirmerman S. Adequacy of prescribing positive airway pressure therapy by mask for sleep apnea on the basis of a partial-night trial. *Am Rev Respir Dis.* 1993 May; 147 (5):1169-74. PMID: 8484627.
  148. Fisher ER, Costantino JP, Fisher B, Redmond CK. Pathologic findings from the National Surgical Adjuvant Breast Project (Protocol 4). Discriminants for 15-year survival. National Surgical Adjuvant Breast and Bowel Project Investigators. *Cancer.* 1993 Mar; 71:2141-2150. PMID: 8443763.
  149. Rogers RM, Donahue M, Costantino JP. Physiologic effects of oral supplemental feeding in malnourished patients with chronic obstructive pulmonary disease. A randomized control study. *Am Rev Respir Dis.* 1992 Dec; 146 (6):1511-1517. PMID: 1456568.
  150. Sanders MH, Black J, Costantino JP, Kern N, Studnicki K, Coates J. Diagnosis of sleep-disordered breathing by half-night polysomnography. *Am Rev Respir Dis.* 1991 Dec; 144 (6):1256-61. PMID: 1741536.

151. Fisher B, Gunduz N, Costantino JP, Fisher ER, Mamounas EP. DNA flow cytometric analysis of primary operable breast cancer. Relation of ploidy and S-phase fraction to outcome of patients in NSABP B-04. *Cancer*. 1991 Oct; 68 (7):1465-1475. PMID: 1893345.
152. Scirba FC, Owens GR, Sanders MH, Costantino JP, Paradis IL, Griffith BP. The effect of obliterative bronchiolitis on breathing pattern during exercise in recipients of heart-lung transplants. *Am Rev Respir Dis*. 1991 Jul; 144 (1):131-5. PMID: 2064118.
153. Zhou SY, Mazumdar S, Redmond CK, Costantino JP. Computations of adjusted rates and lifetime risks from occupational cohort data: a program package using FORTRAN and GLIM. *Comput Biomed Res*. 1991 Feb; 24 (1):29-46. PMID: 2004522.
154. Mazumdar S, Redmond CK, Costantino JP, Patwardhan RN, Zhou SY. Recent developments in the multistage modeling of cohort data for carcinogenic risk assessment. *Environ Health Perspect*. 1991 Jan; 90:271-277. PMID: 2050072.
155. Pollak M, Costantino JP, Polychronakos C, Blauer SA, Guyda H. Effect of tamoxifen on serum insulinlike growth factor I levels in stage I breast cancer patients. *J Natl Cancer Inst*. 1990 Nov; 82 (21):1693-1697. PMID: 2231756.
156. Steen VD, Costantino JP, Shapiro AP, Medsger TA Jr. Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. *Ann Intern Med*. 1990 Sep 1; 113 (5):352-7. PMID: 2382917.
157. Sanders MH, Costantino JP, Johnson JT. Polysomnography early after uvulopalatopharyngoplasty as a predictor of late postoperative results. *Chest*. 1990 Apr; 97 (4):913-9. PMID: 2108846.
158. Werchowski JL, Sanders MH, Costantino JP, Scirba FC, Rogers RM. Inductance plethysmography measurement of CPAP-induced changes in end-expiratory lung volume. *J App Physiol*. 1990 Apr; 68 (4):1732-8. PMID: 2189864.
159. Sanders MH, Costantino JP, Owens GR, Scirba FC, Rogers RM, Reynolds CF, Paradis IL, Griffith BP, Hardesty RL. Breathing during wakefulness and sleep after human heart-lung transplantation. *Am Rev Respir Dis*. 1989 Jul; 140 (1):45-51. PMID: 2502054.
160. Redmond CK, Fisher B, Costantino JP. Treatment of stage I breast cancer: the NSABP experience. *Horm Res*. 1989; 32:175-180. PMID: 2613203.
161. Fisher B, Costantino JP, Redmond C, Poisson R, Bowman D. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. *N Engl J Med*. 1989; 320 (8):479-484. PMID: 2644532.
162. Mazumdar S, Redmond CK, Enterline PE, Marsh GM, Costantino JP. Multistage modeling of lung cancer mortality among arsenic exposed copper-smelter workers. *J Risk Assesment*. 1989; 9:551-563. PMID: 2608948.
163. Scirba FC, Owens GR, Sanders MH, Griffith BP, Hardesty RL, Paradis IL, Costantino JP. Evidence of an altered pattern of breathing during exercise in recipients of heart-lung transplants. *N Engl J Med*. 1988 Nov 3; 319 (18):1186-92. PMID: 3140013.
164. Costantino JP, Kuller LH, Begg L, Redmond CK, Bates MW. Serum level changes after administration of a pharmacologic dose of beta-carotene. *The American journal of clinical nutrition*. 1988 Nov; 48 (5):1277-83. PMID: 3055930.

165. Dong MH, Redmond CK, Mazumdar S, Costantino JP. A Multistage Approach to the Cohort Analysis of Lifetime Lung Cancer Risk Among Steelworkers Exposed to Coke Oven Emissions. *American Journal of Epidemiology*. Am J Epidemiol. 1988 Oct; 128 (4):860-873. PMID: 3421248.
166. Bender MA, Leonard RC, White O Jr, Costantino JP, Redmond CK. Chromosomal aberrations and sister-chromatid exchanges in lymphocytes from coke oven workers. *Mutat Res*. 1988 Sep; 206 (1):11-6. PMID: 3412368.
167. Taylor SR, Blatt J, Costantino JP, Roederer M, Murphy RF. Flow cytometric DNA analysis of neuroblastoma and ganglioneuroma. A 10-year retrospective study. *Cancer*. 1988 Aug 15; 62 (4):749-54. PMID: 3395958.
168. Marsh GM, Costantino JP, Lyons E. Health effects of exposure to Drake Chemical Company superfund site; Mortality among former employees and family members. *J Environ Hlth*. 1988; 50 (7):389-394.
169. Glickman LT, Chaudry IU, Costantino JP, Clack FB, Cypess RH, Winslow L. PICA patterns, toxocariasis, and elevated blood lead in children. *The American Society of Tropical Medicine and Hygiene*. 1981; 301 (1):77-80. PMID: 7212174.
170. Costantino JP, Kuller LH, Perper JA, Cypess RH. An epidemiologic study of homicides in Allegheny County, Pennsylvania. *Am J Epidemiol*. 1977 Oct; 106 (4):314-24. PMID: 910799.

#### **Reviews, Proceedings of Conferences and Symposia (not peer-reviewed), Editorials**

1. McGale P, Taylor C, Correa C, Cutter D, Duane F, Ewertz M, Gary R, Mannu G, ..., Costantino J, & others. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: Meta-analysis of individual patient data for 8135 women in 22 randomized trials. *Lancet*. 2014; 383 (9935):2127-35. PMID: 24496514.

#### **Books, Book Chapters, Monographs**

1. Costantino JP, Anderson SJ, Yothers G. Statistical design and analysis of phase III clinical trials. Ch 73. In: Kuere HM, editor. *Kuerer's Breast Surgical Oncology*. ( pp. 441-450 ) . New York, NY: McGraw-Hill, 2010. (invited).
2. Costantino JP. Benefit/risk assessment in prevention trials. In: D'Agostino R, Sullivan LM, Marssaro J, editors. *Wiley Encyclopedia of Clinical Trials*. ( pp. 1-8 ) . John Wiley and Sons, 2008. (invited).
3. Redmond CK, Costantino JP, Colton T. Challenges in monitoring the Breast Cancer Prevention Trial. In: DeMets DI, Furberg CD, Friedman LM, editors. *Data Monitoring in Clinical Trials: A Case Study Approach*. ( pp. 118-35 ) . New York, NY: Springer, 2006. (invited).
4. Institute of Medicine Committee on Assessing the Need for Clinical Trials of Testosterone Replacement Therapy. In: Liverman CT, Blazer DG, editors. *Testosterone and Aging: Clinical Research Directions*. Washington, DC: The National Academies Press, 2004. (invited).
5. Wickerham DL, Costantino JP. Tamoxifen for chemoprevention. In: Morrow M, Jordon CV, editors. *Managing Breast Cancer Risk*. ( pp. 175-185 ) . Hamilton, Ontario: BC Decker, Inc., 2003. (invited).
6. Wickerham DL, Costantino JP. Breast Cancer prevention: the U.S.A. viewpoint. In: *Breast Cancer Management: Application of Evidence to Patient Care*, 2nd Ed. ( pp. 535-547 ) . Philadelphia, PA: Lippincott, Williams and Wilkins, 2003. (invited).

7. Land SR, Wieand HS, Day R, Ten Have T, Costantino JP, Lang W, Ganz P. Methodological issues in the analysis of quality of life data in clinical trials: illustrations from the National Surgical Adjuvant Breast and Bowel Project (NSABP) Breast Cancer Prevention Trial. In: Mesbah M, Cole B, Klewer ML, editors. *Statistical Design, Measurement and Analysis of Health Related Quality of Life*. ( pp. 71-85 ) . Academic Publishers, 2002. (invited).
8. Costantino JP. Benefit/risk assessment. In: Redmond CK, Colton T, editors. *Biostatistics in Clinical Trials*. ( pp. 18-25 ) . Wiley, 2001. (invited).
9. Costantino JP. Evaluating women for breast cancer risk reduction therapy. In: *American Society of Clinical Oncology Fall Education Book*. ( pp. 208-214 ) . 1999. (invited).
10. Fisher B, Costantino JP, Redmond CK, Wickerham DL. Recent information from the current NSABP trials of adjuvant therapy of breast cancer. In: Salmon SE, editor. *Adjuvant Therapy of Cancer VII*. J.B. Lippencott Company, 1993. (invited).

### Other Publications

1. Costantino JP. Commentary: Tamoxifen reduced the incidence of breast cancer in women at increased risk, but had more adverse events. *Evidence-based Obstet Gynecol* 2003; 5:141-2.
2. Costantino JP, Ganz PA, Day R. Measuring depression in the BCPT. *Oncology Times* 1998; 20 (1):6-7.
3. Costantino JP. Use of diesel equipment in underground coal mines: Health and safety aspects. BCR National Laboratory, Report No. L-1385, January 2, 1984.
4. Costantino JP. Statistical assessment of data from the NCA precipitation quality network. BCR National Laboratory, Report No. L-1432, September 1984.
5. Costantino JP. Assessment of health risk associated with the use of diesel equipment in underground coal mines. Bituminous Coal Research, Inc., Report No. L-1363, June 15, 1983.
6. Costantino JP. Evaluation of coal-mine dust control. Bituminous Coal Research, Inc., Report No. L-1357, March 31, 1983.
7. Costantino JP. Assessment of thoracic particulate levels at surface mining operations. Bituminous Coal Research, Inc., Report No. L-1355, March 31, 1983.
8. Costantino JP. Dust control accomplishments in U.S. underground coal mines. *Proceedings of the Symposium on Control Respirable Coal Mine Dust*, Mine Safety and Health Administration, 73-80, 1983.
9. Costantino JP. Thoracic particulate levels at surface mining operations determined by automated microscopic analysis of hi-vol filters. *Fugitive Dust Issues in the Coal Use Cycle*, Air Pollution Control Association, 209-219, 1983.
10. Costantino JP, Boyer JF. Assessment of health risk associated with the underground use of diesel equipment. Bituminous Coal Research., Report No. L-1328, September 23, 1982.
11. Connelly DJ, Costantino JP. Back injuries in coal mining. Bituminous Coal Research, Inc., Pamphlet No. 4, October, 1982.
12. Costantino, JP. Public health protection and air quality. *Peabody Magazine*, Spring issue, 1982.
13. Costantino JP. Facts about coal workers' pneumoconiosis. Bituminous Coal Research, Inc., Pamphlet No. 2, April 1982.

14. Saltsman RD, Costantino JP. Coal mine dust control and pneumoconiosis research in Europe and the United States. Proceedings of the Twelfth Annual Institute on Coal Mining, Health, Safety, and Research, Mine Safety and Health Administration, 73-78, 1982.
15. Costantino JP. Effects of extreme temperature on population mortality. Bituminous Coal Research, Inc., Topical Assessment Paper, May 29, 1981.
16. Boyer JF, Costantino JP. Evaluation of the effect of coal cleaning on fugitive elements, part III, state-of-the-art: Fate of trace elements in coal during mining, preparation, and utilization. U.S. Department of Energy, Report No. DOE/EV/04427-53, July 1981.
17. Costantino JP. Health effects of respirable coal mine dust: Coal workers' pneumoconiosis. Mining Congress Journal. 1981;67 (10):55-61.
18. Costantino JP. Assessing the adequacy of the national ambient air quality standards for particulates and sulfur oxides. Bituminous Coal Research Inc., Topical Assessment Paper, September 30, 1980.

## RESEARCH

### Current research support

Funding Agency: NSABP Foundation, Inc.  
 Grant Number: NSABP B-13 ARGO Study Planning  
 Title of Grant: Development of statistical design for and review of protocol entitled "A phase III randomized placebo-controlled study evaluating regorafenib following completion of standard chemotherapy for patients with stage III colon cancer"  
 Principal Investigator: Joseph P. Costantino  
 Costantino Role on Grant: PI (sole)  
 Years Inclusive: 7/2015 - 10/2016  
 Percent Effort: 15.0 %  
 Total Direct Costs: \$264,000

Funding Agency: Primary funding Agency is the National Cancer Institute via subcontract with the NRG Oncology Foundation  
 Grant Number: 5UG1CA189867  
 Title of Grant: NRG Oncology Statistics and Data Management Center - NCORP Research Base  
 Principal Investigator: Joseph Costantino  
 Costantino Role on Grant: PI (sole)  
 Years Inclusive: 8/2014 - 7/2019  
 Percent Effort: 10.0 %  
 Total Direct Costs: \$25,177,236

Funding Agency: NSABP Foundation Inc.  
 Grant Number: NSABP Foundation Core Support  
 Title of Grant: NSABP Biostatistical Center  
 Principal Investigator: Joseph P. Costantino

Costantino Role on Grant:	PI (sole)
Years Inclusive:	8/2014 - 7/2019
Percent Effort:	10.0 %
Total Direct Costs:	\$909,091
Funding Agency:	National Cancer Institute
Grant Number:	5U10CA180822
Title of Grant:	NRG Oncology Statistical and Data Management Center
Principal Investigator:	Joseph P. Costantino
Costantino Role on Grant:	PI (multiple)
Years Inclusive:	3/2014 - 2/2019
Percent Effort:	41.7 %
Total Direct Costs:	\$43,240,056
Funding Agency:	NSABP Foundation, INC.
Grant Number:	NSABP B-55 (OlympiA Study) Supplement
Title of Grant:	Supplement to support the implementation of a randomized Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with high risk germline BRCA mutated HER2 negative primary breast cancer
Principal Investigator:	Joseph P. Costantino
Costantino Role on Grant:	PI (sole)
Years Inclusive:	1/2014 - 12/2027
Percent Effort:	5.0 %
Total Direct Costs:	\$1,607,837
Funding Agency:	NSABP Foundation Inc.
Grant Number:	NSABP B-46-I
Title of Grant:	Long-term follow-up of patients in a phase III trial comparing the combination of TC plus bevacizumab to TC alone and to TAC for women with node-positive or high-risk node-negative, HER2-negative breast cancer
Principal Investigator:	Joseph P. Costantino
Costantino Role on Grant:	PI (sole)
Years Inclusive:	5/2009 - 12/2021
Percent Effort:	5.3 %
Total Direct Costs:	\$4,572,935
Funding Agency:	NSABP Foundation Inc.
Grant Number:	NSABP B-50-I (Katherine Study)
Title of Grant:	A randomized, phase III study to evaluate trastuzumab emtansine versus trastuzumab as adjuvant therapy for

patients with Her-2+ breast cancer who have residual tumor present after preoperative therapy

Principal Investigator: Greg Yothers  
Costantino Role on Grant: Co-Investigator  
Years Inclusive: 5/2009 - 12/2021  
Percent Effort: 5.0 %  
Total Direct Costs: \$4,810,701

### **Pending research support**

Funding Agency: NSABP Foundation, Inc  
Grant Number: NSABP C-13 ARGO Study  
Title of Grant: A phase III randomized placebo-controlled study evaluating regorafenib following completion of standard chemotherapy for patients with stage III colon cancer

Principal Investigator: Greg Yothers  
Costantino Role on Grant: Co-Investigator  
Years Inclusive: 11/2016 - 10/2024  
Percent Effort: 15.0 %  
Total Direct Costs: \$5,803,925

### **Past research support**

Funding Agency: National Cancer Institute  
Grant Number: 5 U10 CA 069651  
Title of Grant: CTEP Biostatistical Center for the NSABP (Year 20)  
Principal Investigator: Joseph P. Costantino  
Costantino Role on Grant: PI (sole)  
Years Inclusive: 2/2013 - 1/2014  
Percent Effort: 40.0 %  
Total Direct Costs: \$2,534,758

Funding Agency: National Cancer Institute  
Grant Number: 5 U10 CA069974  
Title of Grant: CCOP Biostatistical Center (Years 17 and 18)  
Principal Investigator: Joseph P. Costantino  
Costantino Role on Grant: PI (sole)  
Years Inclusive: 6/2012 - 5/2014  
Percent Effort: 40.0 %  
Total Direct Costs: \$5,352,751  
Total Amount Awarded: \$8,122,348

Funding Agency: NSABP Foundation INC.  
Title of Grant: GHI Study 5-038

Costantino Role on Grant:	PI (sole)
Years Inclusive:	2/2011 - 1/2012
Total Direct Costs:	\$22,828
Funding Agency:	NSABP Foundation Inc.
Grant Number:	NRG Oncology
Title of Grant:	Supplement to support the alliance of the NSABP, RTOG, and GOG into NRG Oncology Group
Principal Investigator:	Joseph P. Costantino
Costantino Role on Grant:	PI (sole)
Years Inclusive:	2/2011 - 1/2013
Total Direct Costs:	\$518,744
Funding Agency:	National Cancer Institute
Grant Number:	3 U10 CA069651
Title of Grant:	Implementation of the Medidata Rave Clinical Data Management System
Principal Investigator:	Joseph P. Costantino
Costantino Role on Grant:	PI (sole)
Years Inclusive:	9/2010 - 8/2013
Total Direct Costs:	\$809,789
Funding Agency:	National Cancer Institute
Grant Number:	3 U10 CA069651-11S1
Title of Grant:	American Recovery and Reinvestment Act Supplement #2 to Biostatistical Center for the NSABP
Costantino Role on Grant:	PI (sole)
Years Inclusive:	7/2010 - 6/2011
Total Direct Costs:	\$116,622
Funding Agency:	NSABP Foundation INC.
Grant Number:	NSABP C-12 Development
Title of Grant:	Pre-implementation Development for a Phase III Trial to test the value of Bevacizumab Given for Two Years in Combination with 5-FU, Leucovorin, and Oxaliplatin Given for 6 Months in Patients with Stage III Colon Cancer
Principal Investigator:	Joseph P. Costantino
Costantino Role on Grant:	PI (sole)
Years Inclusive:	1/2010 - 9/2010
Total Direct Costs:	\$280,000
Funding Agency:	National Cancer Institute

Grant Number: 3 U10 CA069651-16S1  
Title of Grant: American Recovery and Reinvestment Act Supplement #1 to Biostatistical Center for the NSABP  
Principal Investigator: Joseph P. Costantino  
Costantino Role on Grant: PI (sole)  
Years Inclusive: 9/2009 - 8/2012  
Total Direct Costs: \$300,420

Funding Agency: NSABP Foundation Inc.  
Grant Number: NSABP B-31-Part 2  
Title of Grant: Phase III trial to compare the safety and efficacy of Adriamycin and Cyclophosphamide Followed by Taxol to that of Adriamycin and Cyclophosphamide Followed by Taxol Plus Herceptin in Node-Positive, HER2+ Breast Cancer Patients  
Principal Investigator: Joseph P. Costantino  
Costantino Role on Grant: PI (sole)  
Years Inclusive: 7/2009 - 6/2012  
Total Direct Costs: \$124,800

Funding Agency: NSABP Foundation Inc.  
Grant Number: NSABP B-44-I  
Title of Grant: Phase III trial assessing bevacizumab with trastuzumab adjuvant therapy in HER2+ breast cancer patients (BETH Trial): NSABP B-44-I  
Principal Investigator: Joseph P. Costantino  
Costantino Role on Grant: PI (sole)  
Years Inclusive: 9/2008 - 4/2014  
Percent Effort: 3.0 %  
Total Direct Costs: \$1,137,685  
Total Amount Awarded: \$1,422,106

Funding Agency: National Cancer Institute  
Grant Number: 5 U10 CA069974  
Title of Grant: CCOP Biostatistical Center (Years 12 through 16)  
Principal Investigator: Joseph P. Costantino  
Costantino Role on Grant: PI (sole)  
Years Inclusive: 6/2007 - 5/2012  
Total Direct Costs: \$15,528,005

Funding Agency: NSABP Foundation Inc.  
Grant Number: NSABP B-41

Title of Grant: Phase III trial of neoadjuvant therapy for patients with palpable and operable HER2-positive breast cancer comparing the combination of trastuzumab plus lapatinib to trastuzumab and to lapatinib administered with weekly paclitaxel following AC

Principal Investigator: Joseph P. Costantino  
Costantino Role on Grant: PI (sole)

Years Inclusive: 3/2007 - 6/2014  
Percent Effort: 1.0 %  
Total Direct Costs: \$354,200

Funding Agency: NSABP Foundation Inc.  
Grant Number: Core Support  
Title of Grant: NSABP Biostatistical Center Core Support  
Principal Investigator: Joseph P. Costantino  
Costantino Role on Grant: PI (sole)

Years Inclusive: 8/2006 - 7/2009  
Total Direct Costs: \$845,454

Funding Agency: National Cancer Institute  
Grant Number: 5 U10 CA069651  
Title of Grant: Biostatistical Center for the NSABP (Years 13 through 19)  
Costantino Role on Grant: PI (sole)

Years Inclusive: 2/2006 - 1/2013  
Total Direct Costs: \$18,027,008

Funding Agency: NSABP Foundation Inc.  
Grant Number: Core Support  
Title of Grant: NSABP Biostatistical Center Core Support  
Principal Investigator: Joseph P. Costantino  
Costantino Role on Grant: PI (sole)

Years Inclusive: 8/2005 - 7/2006  
Total Direct Costs: \$259,091

Funding Agency: NSABP Foundation Inc.  
Grant Number: Core Support  
Title of Grant: NSABP Biostatistical Center Core Support  
Principal Investigator: Joseph P. Costantino  
Costantino Role on Grant: PI (sole)

Years Inclusive: 8/2003 - 7/2006  
Total Direct Costs: \$733,000

Funding Agency: National Cancer Institute  
Grant Number: 2 U10 CA069651  
Title of Grant: Biostatistical Center for the NSABP (Years 10 through 12)  
Principal Investigator: Joseph P. Costantino  
Costantino Role on Grant: PI (sole)  
Years Inclusive: 2/2003 - 1/2006  
Total Direct Costs: \$8,295,873

Funding Agency: National Cancer Institute  
Grant Number: 2 U10 CA069974-S1  
Title of Grant: CCOP Biostatistical Center Supplement: STAR Trial (Years 7 through 11)  
Principal Investigator: Joseph P. Costantino  
Years Inclusive: 6/2001 - 5/2007  
Total Direct Costs: \$1,037,844

Funding Agency: National Cancer Institute  
Grant Number: 2 U10 CA069974  
Title of Grant: CCOP Biostatistical Center (Years 7 through 11)  
Principal Investigator: Joseph P. Costantino  
Costantino Role on Grant: Co-Investigator  
Years Inclusive: 6/2001 - 5/2007  
Total Direct Costs: \$2,136,309

Funding Agency: Discovery International  
Title of Grant: Breast cancer risk assessment education for health professionals  
Principal Investigator: Joseph P. Costantino  
Costantino Role on Grant: Co-Investigator  
Years Inclusive: 6/1999 - 12/1999  
Total Direct Costs: \$12,000

Funding Agency: U.S. Environmental Protection Agency  
Title of Grant: Surveillance of Giardia Infections through Analysis of Fecal Samples and Raw Sewage  
Costantino Role on Grant: Co-Investigator  
Years Inclusive: 9/1989 - 10/1991  
Total Direct Costs: \$50,000

Funding Agency: USX Corporation  
Title of Grant: Feasibility Study of Community Health Effects Associated with Coke Oven Emissions-Part B  
Principal Investigator: Carol Redmond

Costantino Role on Grant:	Co-Investigator
Years Inclusive:	7/1989 - 6/1990
Total Direct Costs:	\$50,000
Funding Agency:	Pennsylvania State Dept. of Environmental Resources
Title of Grant:	Feasibility Study of Community Health Effects Associated with Coke Oven Emissions-Part A
Principal Investigator:	Carol Redmond
Costantino Role on Grant:	Co-Investigator
Years Inclusive:	7/1989 - 6/1990
Total Direct Costs:	\$30,000
Funding Agency:	Allegheny County Health Department
Title of Grant:	Feasibility Study of Community Health Effects Associated with Coke Oven Emissions-Part D
Principal Investigator:	Carol Redmond
Costantino Role on Grant:	Co-Investigator
Years Inclusive:	7/1989 - 6/1990
Total Direct Costs:	\$25,000
Funding Agency:	R.J. Lee Group
Title of Grant:	Environmental Health Training Grant
Principal Investigator:	Joseph P. Costantino
Costantino Role on Grant:	PI (sole)
Years Inclusive:	6/1989 - 4/1992
Total Direct Costs:	\$63,390
Funding Agency:	Pennsylvania Dept. of Health
Title of Grant:	Statistical Analysis of the Drake Superfund Site Drake Occupational Health Survey
Principal Investigator:	Gary Marsh
Costantino Role on Grant:	Co-Investigator
Years Inclusive:	4/1985 - 9/1985
Total Direct Costs:	\$16,000
Funding Agency:	Environmental Protection Agency
Title of Grant:	Morbidity Survey of Coke Oven Workers
Principal Investigator:	Carol Redmond
Costantino Role on Grant:	Co-Investigator
Years Inclusive:	1/1984 - 6/1985
Total Direct Costs:	\$24,200

Funding Agency: National Coal Association  
Title of Grant: Statistical Evaluation of Data from the Precipitation Quality Network  
Principal Investigator: Joseph P. Costantino  
Costantino Role on Grant: PI (sole)  
Years Inclusive: 7/1983 - 6/1984  
Total Direct Costs: \$31,700

Funding Agency: Environmental Protection Agency  
Title of Grant: Clinical Evaluation of Health Status Among Coke Oven Workers  
Principal Investigator: Carol Redmond  
Costantino Role on Grant: Co-Investigator  
Years Inclusive: 6/1983 - 12/1984  
Total Direct Costs: \$36,300

Funding Agency: Consolidation and Peabody Coal Companies  
Title of Grant: Assessment of Coal Related Environmental and Occupational Health Risk  
Principal Investigator: Joseph P. Costantino  
Costantino Role on Grant: PI (sole)  
Years Inclusive: 1/1983 - 12/1984  
Total Direct Costs: \$34,200

Funding Agency: Environmental Protection Agency  
Title of Grant: Cancer Risk Assessment Based on Coke Oven Workers Mortality  
Principal Investigator: Carol Redmond  
Costantino Role on Grant: Co-Investigator  
Years Inclusive: 1/1983 - 6/1989  
Total Direct Costs: \$303,800

Funding Agency: Kerr McGee Coal Corporation  
Title of Grant: Assessment of Health Risk Associated with Use of Diesel Equipment in Underground Coal Mines  
Principal Investigator: Joseph P. Costantino  
Costantino Role on Grant: PI (sole)  
Years Inclusive: 6/1982 - 9/1982  
Total Direct Costs: \$9,700

Funding Agency: American Mining Congress

Title of Grant:	Assessment of Respirable Particulate Levels at Surface Mining Operations
Principal Investigator:	Joseph P. Costantino
Costantino Role on Grant:	PI (sole)
Years Inclusive:	3/1982 - 3/1983
Total Direct Costs:	\$70,000
Funding Agency:	Reitz Coal Company
Title of Grant:	Evaluation of Respirable Dust Levels at Coal Preparation Plant
Principal Investigator:	Joseph P. Costantino
Costantino Role on Grant:	PI (sole)
Years Inclusive:	2/1982 - 6/1982
Total Direct Costs:	\$6,200
Funding Agency:	North American and Old Ben Coal Companies
Title of Grant:	Analysis of Federal Coal Mine Safety and Health Legislation
Principal Investigator:	Joseph P. Costantino
Costantino Role on Grant:	PI (sole)
Years Inclusive:	1/1982 - 12/1982
Total Direct Costs:	\$14,900
Funding Agency:	National Coal Association
Title of Grant:	Environmental Health Risk Associated with Mining, Preparation and Utilization of Coal
Principal Investigator:	Joseph P. Costantino
Costantino Role on Grant:	PI (sole)
Years Inclusive:	1/1980 - 12/1981
Total Direct Costs:	\$140,000

### **OTHER SCHOLARLY ACTIVITIES**

#### **Manuscript Reviewer**

2002 - Present	Statistical Reviewer, Clinical Breast Cancer
2001 - Present	Statistical Reviewer, Lancet
1999 - Present	Statistical Reviewer, Statistics in Medicine
1988 - Present	Statistical Reviewer, Journal of the National Cancer Institute
1987 - Present	Statistical Reviewer, Journal of Clinical Oncology

#### **Grant Reviewer**

2004 - 2005	Member, Statistical Reviewer, Site Visit Review Committee - National Cancer Institute, Committee on Renewal of the EORTC Cooperative Group Data Center.
-------------	---

2003 Statistical Reviewer, Women's Health Initiative Clinical Trial and Observational Study Follow-up Study Proposal Concept Review Committee-National Heart Blood and Lung Institute.

2002 Member, Statistical Reviewer, Review Panel-National Cancer Institute, Small Grants Program for Cancer Prevention Research.

1999 Statistical Reviewer, Ad Hoc Review Committee-National Cancer Institute, Efficacy of Mammography Screenings Ages 40-49.

1999 Statistical Reviewer, Site Visit Review Committee-National Cancer Institute, Cancer Prevention Studies Branch Review of Intermural Program.

1997 Statistical Reviewer, Site Visit Review Committee-National Cancer Institute, Cancer Screening Program Project Grant. Northern California Cancer Center, Belmont, California.

1996 Statistical Reviewer, Site Visit Review Committee-National Cancer Institute, Cancer Screening Program Project Grant. Northern California Cancer Center, Belmont, California.

1993 Statistical Reviewer, Ad Hoc Review Committee-National Institute of Heart, Lung, and Blood, Clinical Centers and Coordinating Center for Nutritional Aspects of Blood Pressure Study.

1991 Statistical Reviewer, Site Visit Review Committee - National Cancer Institute, Cancer Screening Program Project Grant, Northern California Cancer Center, Belmont California.

1990 Statistical Reviewer, Special Review Committee-National Institute of Heart, Lung, and Blood, Asymptomatic Cardiac Ischemia Pilot Study: Clinical Units

1990 Statistical Reviewer, Ad Hoc Review Committee-National Cancer Institute, Preventive Clinical Trials Utilizing Intermediate Endpoints and Their Modulation by Chemopreventive Agents. Chevy Chase, Maryland.

1989 Statistical Reviewer, Special Review Committee-National Institute of Dental Research, Specialized Caries Research Center.

1988 Statistical Reviewer, Research Review Committee

1986 Statistical Reviewer, Site Visit Review Committee-National Heart, Lung, and Blood Institute, Coronary Program Project Grant, State University of New York, School of Medicine.

1986 Statistical Reviewer, Site Visit Review Committee-National Heart, Lung, and Blood Institute, Pulmonary SCOR Grant, University of Rochester, School of Medicine.

1985 - 1986 Statistical Reviewer, Ad Hoc Review Committee-National Heart, Lung, and Blood Institute, Mechanisms Responsible for Age Related Increases in Blood Pressure.

### **Conference Planning & Review**

2012 - 2014 Chair, Statistical Review Subcommittee, Annual Meeting of the American Society for Clinical Oncology Scientific Program Committee

## INVITED PRESENTATIONS

1. Risk prediction, benefit/risk assessment and risk communication in breast cancer chemoprevention. (Presenter, Invited Presentation). Presented at: The National Institutes of Health Biostatistics Symposium: Statistics in Biomedical Research-Making and Translating New Discoveries; 2012 Nov 10; Bethesda, MD.
2. Statistics for cancer control/prevention researchers. Presented at: National Cancer Institute Meeting of the Cancer Prevention and Control Investigator; 2012 Mar 20; Bethesda, MD.
3. Update of the NSABP study of tamoxifen and raloxifene (STAR) P-2 trial in preventing breast cancer. Presented at: 101st Annual Meeting of the American Association of Cancer Research (Invited Presentation); 2010 Apr 19; Washington, DC.
4. The impact of systemic therapy following ductal carcinoma in situ. Diagnosis and Management of Ductal Carcinoma in Situ. Presented at: NIH State-of-the-Science Conference. (Invited Presentation); 2009 Sep 23; Washington, DC.
5. Breast Cancer Prevention. (Presenter, Invited Presentation). Presented at: Global Health in the 21st Century: The latest Successful Perceptions.; 2008 Oct 16; Washington, DC.
6. Chemoprevention of Breast Cancer: Communicating the benefits and risks. (Presenter, Invited Presentation). Presented at: Memorial Sloan-Kettering Cancer Center. Seminars in Prevention, Control and Population Research.; 2008 Oct 14.
7. Monitoring Multiple Endpoints in Prevention Trials. Presented at: 5th Annual Meeting of the American Association of Cancer Research (Presenter, Invited Presentation); 2006 Nov 15; Boston, MA.
8. Initial Findings from the NSABP P-2 Breast Cancer Prevention Trial. 2006 Oct 3; Grand Rounds, Massachusetts General Hospital (Presenter, Invited Presentation).
9. Breast Cancer Risk: Accurately Relating Risk to Patients and Risk Reduction Strategies.(Presenter, Invited Presentation). Presented at: 6th Annual Symposium on Advances in Comprehensive Breast Care.; 2005 Nov 12; University of Virginia School of Medicine. Charlottesville, Va.
10. The U.S. breast cancer prevention trials (NSABP-P1, MORE, STAR). Presented at: Meeting of the International Breast Cancer Trialist Group. (Invited presentation); 2004 Mar; St. Gallen, Switzerland.
11. Risk Assessment in Clinical Trials. Presented at: Joint Statistical Meetings of the American Statistical Association (Presenter, Invited Presentation); 2002 Aug 14; New York , NY.
12. Looking for treatment effect in genetic sub-studies of randomized trials: do we need to genotype controls? Presented at: Joint Statistical Meetings of the American Statistical Association. (Invited presentation); 2002 Aug 14; New York, NY.
13. Composition and independence of data monitoring committees. Presented at: 23rd Annual Meeting of the Society for Clinical Trials. (Presenter, invited presentation); 2002 May 15; Arlington, VA.
14. Risk Assessment in the STAR trial. Presented at: Annual Meeting of the International Biometrics Society: ENAR. (Presenter, invited presentation); 2001 Mar 28; Charlotte, NC.

15. Risk/benefit assessment: Clinical trial versus clinical practice settings. Presented at: NIH Workshop on Selective Estrogen Receptor Modulators. (Presenter, Invited presentation); 2000 Apr 26; Bethesda, MA.
16. Evaluating women for preventive prescription: risk assessment and counseling. (Presenter, Invited Presentation). 2000 Feb 11; Michigan State University, East Lansing MI.
17. Breast cancer risk assessment. Presented at: Annual San Antonio Breast Cancer Symposium (Presenter, Invited Presentation); 1999 Dec 10; San Antonio, TX.
18. Evaluating women for breast cancer risk reduction therapy. Presented at: Annual Fall Meeting of the American Society of Clinical Oncology (Presenter, Invited Presentation); 1999 Nov 5; San Francisco, CA.
19. Breast cancer risk assessment and review of the Gail model. Presented at: Symposium on Breast Cancer Prevention for the High Risk Woman: A role for the OBGYN Physician (Presenter, Invited Presentation); 1999 Oct 25; Lahaina, HI.
20. Methods for quantifying breast cancer risk. Presented at: American Cancer Society Workshop on Breast Cancer Risk Communication. (Presenter, Invited Presentation); 1999 Oct 4; Hilton head, SC.
21. Evaluating women for breast cancer prevention. Presented at: Ottawa Regional Cancer Center (Presenter, Invited Presentation); 1999 Sep 24; Ottawa, ON.
22. The risks and benefits of tamoxifen treatment. Presented at: Annual Joint Meetings of American Statistical Association. (Presenter, Invited Presentation); 1999 Aug 10; Baltimore, MD.
23. Breast cancer prevention and the NSABP Star trial. 1999 Jul 16; Yale University School of Medicine, New Haven CT (Presenter, Invited Presentation).
24. Using the Gail model for predicting breast cancer risk. Presented at: Roundtable on the Role of the Primary Care Physician in Breast Control. (Presenter, Invited Presentation); 1999 Jun 11; Washington, DC.
25. Results of the Breast Cancer Prevention Trial. Presented at: (Presenter, Invited Presentation); 1999 Jun 10; SUNNY Health Science Center. Syracuse, NY.
26. The breast cancer prevention trial (BCPT). Presented at: Annual Meeting of the American Statistical Association, Pittsburgh Chapter (Presenter, Invited Presentation); 1999 May 12; Pittsburgh, PA.
27. Tamoxifen and the prevention of breast cancer: what can we learn about disease prevention from clinical trials? Presented at: Seventh Annual Symposium on Clinical Trials. (Presenter, Invited Presentation); 1998 Oct 23; San Francisco, CA.
28. Homogeneity of treatment effect across ages: comparing the risks and benefits in the BCPT. Presented at: National Cancer Institute Workshop on Breast Cancer Risk Assessment and Prevention.(Presenter, Invited Presentation); 1998 Jul 7; Chantilly, Va.
29. The study of breast cancer genes in the breast cancer prevention trial. Presented at: Annual Meeting of the International Biometric Society (Presenter, Invited Presentation); 1997 Mar 25.
30. Statistical and Design Issues of the NSABP Breast Cancer Prevention Trial. Presented at: Annual American Public Health Association. (Presenter, Invited Presentation); 1993 Sep 27; San Francisco, CA.

31. NSABP Breast Cancer Prevention Trial. Presented at: Annual Meeting of the Pennsylvania Public Health Association.(Presenter, Invited Presentation); 1993 Apr 2; Pittsburgh, PA.

### **OTHER PRESENTATIONS**

1. Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: 5-year outcomes of NSABP protocol B-41. Presented at: Annual Meeting of the American Society for Clinical Oncology; 2016 Jun 6; Chicago, IL.
2. Phase III trial to determine if chest wall and regional nodal radiation (CWRNRT) post mastectomy or the addition of regional node radiotherapy to breast radiotherapy post breast-conserving surgery reduces invasive breast cancer recurrence-free interval in patients with positive axillary nodes who are ypNO after neoadjuvant chemotherapy. Presented at: Annual Meeting of the American Society for Clinical Oncology.; 2016 Jun 5; Chicago, IL.
3. Patient-reported outcome results, NRG Oncology/NSABP B-35: A clinical trial of anastrozole vs tamoxifen in postmenopausal patients with DCIS undergoing lumpectomy plus radiotherapy. Presented at: San Antonio Breast Cancer Symposium; 2015 Dec 11; San Antonio. TX.
4. Primary results of NRG/NSABPB-35: A clinical trial comparing anastrozole with tamoxifen in postmenopausal patients with ductal carcinoma in situ undergoing lumpectomy with radiotherapy. Presented at: American Society for Clinical Oncology; 2015 Jun 1; Chicago, IL.
5. Final updated results of the NRG Oncology/NSABP protocol P-2: Study of Tamoxifen and Raloxifene (STAR) in preventing breast cancer. Presented at: American Society of Clinical Oncology; 2015 May 30; Chicago, IL.
6. Vasomotor symptoms, BMI, and adherence to tamoxifen in the National Surgical Adjuvant Breast and Bowel Project (NSABP) Breast Cancer Prevention Trial (P-1). Presented at: American Society for Clinical Oncology; 2015 May 30; Chicago, IL.
7. A surrogate gene expression signature of tumor infiltrating lymphocytes (TILs) predict degree of benefit degree of benefit from trastuzumab added to standard adjuvant chemotherapy in NSABP (NRG) trial B-31 for HER2+ breast cancer. Presented at: American Association for Cancer Research; 2015 Apr 20; Philadelphia, PA.
8. Efficacy of adjuvant trastuzumab compared with no trastuzumab for patients with HER2-positive breast cancer and tumors greater than or equal to 2.0 cm: A meta-analysis of randomized trastuzumab trials. Presented at: American Society for Clinical Oncology; 2014 May 31; Chicago, IL.
9. The prognosis of small HER2+ breast cancers: A meta-analysis of the randomized trastuzumab trials. Presented at: San Antonio Breast Cancer Symposium; 2013 Dec 13; San Antonio TX,.
10. Primary results from BETH, a phase 3 controlled study of adjuvant chemotherapy and trastuzumab with/without bevacizumab in patients with HER2-positive, node-positive or high risk node-negative breast cancer. Presented at: San Antonio Breast Cancer Symposium; 2013 Dec 11; San Antonio, TX.
11. 10 year follow-up results of occult detected sentinel node disease: NSABP B-32, a randomized phase III clinical trial to compare sentinel node resection to

- conventional axillary dissection in clinically node-negative breast cancer patients. Presented at: San Antonio Breast Cancer Symposium; 2013 Dec 11; San Antonio TX,.
12. Body Mass index at diagnosis and breast cancer survival prognosis among clinical trial populations: Results from NSABP B-30, B-34, B-38. Presented at: San Antonio Breast Cancer Symposium; 2013 Dec 11; San Antonio TX,.
  13. 10-yr follow up results of NSABP B-32, a randomized phase III clinical trial to compare sentinel node resection to conventional axillary dissection in clinically node-negative breast cancer patients. Presented at: American Society of Clinical Oncology; 2013 Jun 1; Chicago, IL.
  14. The 21-gene Recurrence Score predicts risk of locoregional recurrence (LRR) in node (+), ER (+) breast cancer after adjuvant chemotherapy and tamoxifen: Results from NSABP B-28. Presented at: Society of Surgical Oncology; 2013 Mar 8; Washington, DC.
  15. Meta-analysis results from the collaborative trials in neoadjuvant breast cancer (CTNeoBC). Presented at: 35th Annual San Antonio Breast Cancer Symposium; 2012 Dec 5; San Antonio TX,.
  16. Association between the 21-gene recurrence score and benefit from adjuvant paclitaxel in node-positive, ER-positive breast cancer patients: Results from NSABP B-28. Presented at: 35th Annual San Antonio Breast Cancer Symposium; 2012 Dec 5; San Antonio TX,.
  17. Prognostic impact of the 21-gene Recurrence Score on disease-free and overall survival of node-positive, ER-positive breast cancer patients treated with adjuvant chemotherapy: Results from NSABP B-28. Presented at: American Society of Clinical Oncology Breast Cancer Symposium; 2012 Sep 14; San Francisco, CA,.
  18. Definitive analysis of a randomized trial comparing dose-dense AC->paclitaxel plus gemcitabine with DD AC-> and with docetaxel, doxorubicin, and cyclophosphamide in women with operable, node-positive breast cancer. Presented at: 48th Annual Meeting of the American Society of Clinical Oncology; 2012 Jun 5; Chicago, IL.
  19. Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: NSABP protocol B-41. Presented at: 48th Annual Meeting of the American Society of Clinical Oncology; 2012 Jun 3; Chicago, IL.
  20. NSABP Protocol B-34: A clinical trial comparing adjuvant clodronate vs placebo in early stage breast cancer patients receiving systemic chemotherapy and/or tamoxifen or no therapy - final analysis. Presented at: 34th Annual San Antonio Breast Cancer Symposium; 2011 Dec; San Antonio, TX.
  21. Early toxicity results with 3-D conformal external beam therapy (CEBT) from the NSABP B-39/RTOG 0413 Accelerated Partial Breast Irradiation (APBI) Trial. Presented at: 53rd Annual Meeting of the American Society for Radiation Oncology; 2011 Oct; Miami, FL.
  22. The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP Protocol B-40. Presented at: 47th Annual Meeting of the American Society of Clinical Oncology; 2011 Jun 6; Chicago, IL.
  23. Cigarette smoking, fitness, and alcohol use as predictors of cancer outcomes among women in the National Surgical Breast and Bowel Projects (NSABP)

- Breast Cancer Prevention Trial (BCPT). Presented at: 47th Annual Meeting of the American Society of Clinical Oncology; 2011 Jun 6; Chicago, IL.
24. The effect on pCR of bevacizumab and/or antimetabolites added to standard. Presented at: 2011 ASCO Annual Meeting; 2011 Jun 4-8; Chicago, IL.
  25. Comparing the prediction of chemotherapy benefit in patients with node-negative, ER-positive breast cancer using the recurrence score and a new measure that integrates clinical and pathologic factors. Presented at: 33rd Annual San Antonio Breast Cancer Symposium; 2010 Dec 10; San Antonio, TX.
  26. Comparison of African American and Caucasian patients in radiotherapy delivery in National Surgical Adjuvant Breast and Bowel Project breast cancer treatment trials. Presented at: 52nd Annual Meeting of the American Society for Therapeutic Radiology and Oncology.; 2010 Nov 1; San Diego, CA.
  27. Early toxicity results with 3-D conformal external beam therapy (CEBT) from the NSABP B-39/RTOG 0413 accelerated partial breast irradiation trial. Presented at: Annual Meeting of the American Society of Clinical Breast Cancer Symposium.; 2010 Oct 2; National Harbor, MD.
  28. Primary outcome results of NSABP B-32, a randomized phase III clinical trial to compare sentinel node resection to conventional axillary dissection in clinically node-negative breast cancer patients. Presented at: 46th Annual Meeting of the American Society of Clinical Oncology; 2010 Jun 6; Chicago, IL.
  29. Recurrence risk of node-negative and ER-positive early stage breast cancer patients combining Recurrence Score, pathologic, and clinical information: a meta analysis approach. Presented at: The 2010 ASCO Annual Meeting; 2010 Jun; Chicago, IL.
  30. Correlation of levels of Akt phosphorylation at Ser473 with benefit from paclitaxel chemotherapy in NSABP B-28 patients with node-positive breast cancer. Presented at: 45th Annual Meeting of the American Society of Clinical Oncology; 2009 May 31; Orlando, FL.
  31. NSABP B-30: Definitive analysis of patient outcome from a randomized trial evaluating different schedules and combinations of adjuvant therapy containing doxorubicin, docetaxel and cyclophosphamide in women with operable, node-positive breast cancer. Presented at: 31st Annual San Antonio Breast Cancer Symposium; 2008 Dec 14; San Antonio, TX.
  32. NSABP B-30: Definitive analysis of quality of life (QOL) and menstrual history (MH) outcomes from a randomized trial evaluating different schedules and combinations of adjuvant therapy containing doxorubicin, docetaxel and cyclophosphamide in women with operable, node-positive breast cancer. Presented at: 31st Annual San Antonio Breast Cancer Symposium; 2008 Dec 14; San Antonio, TX.
  33. Predictive factors for which a sentinel lymph node biopsy can be avoided. Presented at: Annual Meeting of the Society of Surgical Oncology.; 2008 Mar 15.
  34. Benefit from adjuvant trastuzumab may not be confined to patients with IHC 3+ and/or FISH positive tumors: Central testing results from NSABP B-31. Presented at: 43rd Annual Meeting of the American Society of Clinical Oncology; 2007 Jun 5; Atlanta, GA.

35. Long term outcomes after invasive breast tumor recurrence (IBTR) in women with DCIS in NSABP B-17 and B-24. Presented at: 43rd Annual Meeting of American Society of Clinical Oncology; 2007 Jun 4; Atlanta, GA.
36. Five-year update of cardiac dysfunction on NSABP B-31, a randomized trial of sequential doxorubicin/cyclophosphamide (AC) followed by paclitaxel (T) vs. AC followed by T with trastuzumab (H). Presented at: 43rd Annual Meeting of the American Society of Clinical Oncology; 2007 Jun 4; Atlanta, GA.
37. The Study of Tamoxifen and Raloxifene (STAR): Change in patient-reported outcomes (PROs) after the end of treatment. Presented at: 43rd Annual Meeting of Society of Clinical Oncology; 2007 Jun 3; Atlanta, GA.
38. Chemosensitivity and stratification by a five monoclonal antibody IHC test in the NSABP B20 trial. Presented at: Annual Meeting of the American Society of Clinical Oncology; 2007 Jun 3; Atlanta, GA.
39. Predictive factors associated with invasive lobular breast cancer after neoadjuvant chemotherapy. Presented at: Society of Surgical Oncology's 60th Annual Cancer Symposium; 2007 Mar 16; Washington, DC.
40. Benefit from exemestane (EXE) as extended adjuvant therapy after 5 years of tamoxifen (TAM): intent-to-treat analysis of NSABP B-33. Presented at: 29th Annual San Antonio Breast Cancer Symposium; 2006 Dec 15; Washington, DC.
41. The effect of tamoxifen versus raloxifene on the risk of developing noninvasive breast cancer in the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. Presented at: San Antonio Breast Cancer Symposium; 2006 Dec 15.
42. Fracture Results from the Study of Tamoxifen and Raloxifene (STAR). Presented at: 28th Annual Meeting of the American Society for Bone Mineral Research; 2006 Sep 15; Philadelphia, PA.
43. The Study of Tamoxifen and Raloxifene (STAR): Initial findings from the NSABP P-2 Breast Cancer Prevention Study. Presented at: 42nd Annual Meeting of the American Society of Clinical Oncology; 2006 Jun 5; Atlanta, GA.
44. Relationship between tumor gene expression and recurrence in stage II/III colon cancer: Quantitative RT-PCR assay of 757 genes in fixed paraffin-embedded (FPE) tissue. Presented. Presented at: American Society of Clinical Oncology Annual Meeting; 2006 Jun 2; Atlanta, GA.
45. Continued technical results of NSABP B-32: Does a positive sentinel node biopsy require axillary dissection? Presented at: 28th Annual San Antonio Breast Cancer Symposium; 2005 Dec 9; San Antonio, TX.
46. Survival after IBTR in NSABP Node Negative Protocols B-13, B-14, B-19, B-20 and B-23. Presented at: 41st Annual Meeting of the American Society of Clinical Oncology.; 2005 May 16; Orlando, FL.
47. Comparison of self-reported outcomes with arm functional measurements in early breast cancer patients undergoing nodal biopsy in NSABP protocol B-32. Presented at: 41st Annual Meeting of the American Society of Clinical Oncology; 2005 May 15; Orlando, FL.
48. Determinants of participation in the study of tamoxifen and raloxifene (STAR): Experience of a minority-based community oncology program. Presented at: 41st Annual Meeting of the American Society of Clinical Oncology; 2005 May 15; Orlando, FL.

49. Amenorrhea in premenopausal women on the doxorubicin (A) and cyclophosphamide (C) to docetaxel (T) arm of the NSABP B-30: Preliminary results. Presented at: 41st Annual Meeting of the American Society of Clinical Oncology; 2005 May 15; Orlando, FL.
50. Expression of the 21 genes in the recurrence score assay and tamoxifen clinical benefit in the NSABP study B-14 of node negative, estrogen positive breast cancer. Presented at: 41st Annual Meeting of the American Society of Clinical Oncology.; 2005 May 15; Orlando, FL.
51. Factor V Leiden (FVL) and prothrombin G20210A (PTG) mutations and risk of thromboembolic events (TE) in NSABP P-1, the Breast Cancer Prevention Trial (BCPT). Presented at: 25th Annual San Antonio Breast Cancer Symposium; 2002 Dec; San Antonio, TX.
52. Benign breast disease and the risk of subsequent invasive breast cancer: findings from the National Surgical Adjuvant Breast and Bowel Project's Breast Cancer Prevention Trial. Presented at: 25th Annual San Antonio Breast Cancer Symposium; 2002 Dec; San Antonio, TX.
53. Data Monitoring Committees: Internet Audio Conference. Presented at: FDA News. (Presenter, Invited Presentation); 2001 Dec 18.
54. The effect of Tamoxifen on benign breast disease. Finding from the National Surgical Breast and Bowel Project (NSABP) Breast Cancer Prevention Trial (BCPT). Presented at: 42th Annual San Antonio Breast Cancer Symposium; 2001 Dec 12; San Antonio, TX.
55. The Study of Tamoxifen and Raloxifene: Preliminary enrollment data from a randomized breast cancer reduction trial. Presented at: 24th Annual San Antonio breast Cancer Symposium.; 2001 Dec 11; San Antonio, TX.
56. Tamoxifen and breast cancer incidence among women with BRCA1 and BRCA2 mutations: A genomics resequencing project embedded in the Breast Cancer Prevention Trial. Presented at: Annual Meeting of the American Society for Clinical Oncology.; 2001 May 13; San Francisco, CA.
57. Incidence of contralateral breast cancer, endometrial cancer and thromboembolic events in African women receiving tamoxifen treatment for primary breast cancer. Presented at: Annual Meeting of the American Society for Clinical Oncology. (Invited Presentation); 2000 May 22; New Orleans, LA.
58. Understanding breast cancer risk factors. Presented at: Annual Lynne Sage Breast Cancer Symposium; 1999 Oct 1; Chicago, IL.
59. National Surgical Breast and Bowel Project (NSABP) Breast Cancer Prevention Trial (BCPT): Summary analysis of transvaginal sonography and endometrial biopsy in detecting endometrial pathology. Presented at: Annual Meeting of the American Society of Clinical Oncology.; 1999 May 18; Atlanta, GA.
60. Rates of invasive and noninvasive breast cancer by history of LCIS and atypical hyperplasia for participants of the BCPT. Presented at: Annual Meeting of the American Society of Clinical Oncology; 1999 May 18; Atlanta, GA.
61. Electronic monitoring of participant adherence in the NSABP Breast Cancer Prevention Trial. Presented at: Annual Meeting of the Society for Clinical Trials.; 1998 May 20; Atlanta, GA.

62. Demographic characteristics and quality of life factors among participants of the Breast Cancer Prevention Trial. Presented at: Annual Meeting of the Society for Clinical Trials.; 1998 May 19; Atlanta, GA.
63. Findings from the NSABP Breast Cancer Prevention Trial. Presented at: Annual Meeting of the American Society of Clinical Oncology.; 1998 May 18; Los Angeles, CA.
64. Mortality experience of women in the high nickel alloys industry. Presented at: International Conference on Women's Health: Occupation, Cancer and Reproduction; 1998; Reykjavik, Iceland.
65. Global monitoring of prevention trials: the Breast Cancer Prevention Trial experience. Presented at: Annual Meeting of the Society for Clinical Trials.; 1997 Jul 10; Boston, MA.
66. Risk communication strategies during an ongoing clinical trial: Protecting participant safety without causing unnecessary panic, the Breast Cancer Prevention Trial experience. Presented at: Annual Meeting of the Society of Clinical Trials. (Presenter); 1997 Jul 8; Boston, MA.
67. Effect of selected prognostic markers on node-negative breast cancer patients with ER-positive tumors: 10-year results from NSABP B-14. Presented at: Annual Meeting of the American Society of Clinical Oncology; 1997 May 19; Denver, CO.
68. Tumor Size, Ploidy, S-phase and ERB B-2 Markers in Patients with Node Negative ER-positive Tumors. Findings from NSABP B-14. Presented at: Annual Meeting of the American Society of Clinical Oncology (Presenter); 1994 May 16; Dallas, TX.
69. Adjuvant Therapy for Node Negative Breast Cancer: An Update of NSABP Findings. Presented at: Annual Meeting of the American Association for Clinical Oncology. (Presenter); 1993 May 17; Orlando, FL.
70. Cancer mortality experience of women employed in the high nickel alloys industry. Presented at: International Conference on Women's Health: Occupation and Cancer; 1993; Baltimore, MD.
71. Long-term Cause-Specific Mortality Pattern Among Coke Oven Workers in Allegheny County. (Presenter, invited presentation). Presented at: Annual Meeting of the Pennsylvania Public Health Association. (Presenter, Invited Presentation); 1989 Sep; Pittsburgh, PA.
72. Recent Developments in the Multistage Modeling of Cohort Data for Carcinogenic Risk Assessment. Presented at: Seventh Symposium of the Center for Environmental Epidemiology entitled; 1989; Pittsburgh, PA.
73. A Comparison of Survival Between White and Black Breast Cancer Patients: Results from NSABP B-09. Presented at: Annual Meeting of the American Society of Clinical Oncology.; 1987 May 19; Atlanta, GA.
74. Effect of Daily Administration of Beta-Carotene Supplementation Within a High Risk Population. Presented at: Annual Meeting of the Pennsylvania Public Health Association.; 1986 Oct 10; State College, Pennsylvania.
75. The Relationship Between Particulate Matter Collected by Co-located PM10 and Hi-Vol Samplers. Presented at: 77th Annual Meeting of Air Pollution Control Association.; 1984 Jun 26; San Francisco, CA.
76. Assessment of the Proposed Rules for the National Ambient Air Quality Standard for Particulate Matter and the Ambient Air Monitoring Reference

- Methods. Presented at: Testimony before the Environmental Protection Agency. (Presenter); 1984 Apr 30; Washington, DC.
77. Evaluating the Adequacy of Mining Health and Safety Proposal Rule 3007. Presented at: Testimony before the Illinois Department of Mines and Minerals (Presenter); 1983 Nov 14; Springfield, IL.
  78. Use of Diesel Equipment in Underground Coal Mines: Safety and Health Aspects. Presented at: Testimony before the Illinois Department of Mines and Minerals. (Presenter); 1983 Nov 14; Springfield, IL.
  79. Assessment of the Health Risk Associated with the Use of Diesel Equipment in Underground Mines. Presented at: 38th Annual Meeting of the American Institute of Mining, Metallurgical, and Petroleum Engineers. (Presenter); 1983 Nov 11; Pittsburgh, PA.
  80. Dust Control Accomplishments in U.S. Underground Coal Mines: Controlling the Risk of Coal Workers' Pneumoconiosis. Presented at: National Symposium on Control of Respirable Coal Mine Dust. (Presenter); 1983 Oct 5; Beckley, West Virginia.
  81. Clean Air Act. Mining Industry Perspectives of a New Particulate Standard for Ambient Air Quality. Presented at: 1983 Annual Meeting of the American Mining Congress (Presenter); 1983 Sep 13; San Francisco, CA.
  82. Assessment of Thoracic Particulate Levels at Surface Mining Operations. Presented at: 76th Annual Meeting of the Air Pollution Control Association.; 1983 Jun 23; Atlanta, GA.
  83. Thoracic Particulate Level at Surface Mining Operations Determined by Automated Microscopic Analysis of Hi-Vol Filters. Presented at: Air Pollution Control Association Specialty Conference on Fugitive Dust Issues in the Coal Use Cycle.; 1983 Apr 12; Pittsburgh, PA.
  84. The Criteria Document for Sulfur Oxides and Particulate Matter. Presented at: 1982 Annual Meeting of the American Mining Congress (Presenter); 1982 May 10; St. Louis, MO.
  85. Coal Mine Dust Control and Pneumoconiosis Research in Europe and the United States. Presented at: Twelfth Annual Institute on Coal Mining Health, Safety and Research.; 1981 Aug 26; Blacksburg, VA.
  86. Health Effects of Respirable Coal Dust: Coal Workers' Pneumoconiosis. Presented at: 1981 Annual Meeting of the American Mining Congress (Presenter); 1981 May 11; St. Louis, MO.
  87. Assessing the Adequacy of the National Ambient Air Quality Standards for Particulates and Sulfur Oxides. Presented at: Clean Air Act Symposium. (Presenter); 1981 Apr 14; Denver, CO.
  88. Setting Health Standards for Ambient Concentrations of Particulate Matter and Sulfur Dioxide. Presented at: Clean Air Act Workshop of the National Coal Association. (Presenter); 1981 Feb 18; Washington, DC.
  89. Homicides in Allegheny County, Pennsylvania. Presented at: Annual Meeting of the Society for Epidemiologic Research. (Presenter); 1976 Jun 17; Toronto, Canada.

## TEACHING

### Graduate Courses

Year(s)	Course Number & Title	Role
2003 - 2004	Epidemiology-2160, Infectious Disease Epidemiology	Co-instructor
2002 - 2006	Epidemiology-2182, Design of Clinical Trials II: Contemporary Issues	Co-instructor
2000 - 2005	Biostatistics-2062, Clinical Trials: Methods and Practice	Co-instructor
2000 - 2002	Epidemiology-2181, Design of Clinical Trials	Co-instructor
1999 - 2006	Epidemiology-2100, Principles of Epidemiology	Co-instructor
1998 - 2000	Clinical Epidemiology and Biostatistics	Co-instructor
1996 - 1998	Public Health-2001, Integrative Course in Public Health	Primary Instructor
1985 - 2013	Biostatistics-2045, Statistical Methods in Public Health	Primary Instructor
1984 - 1988	Biostatistics-2011, Principles of Statistical Reasoning	Primary Instructor
1973 - 1976	Epidemiology-201, Principles of Epidemiology	Primary Instructor

### Precepting/Experiential

Year(s)	Course Number & Title	Role
2012 - 2014	Yang Zhang Graduate Student Researcher	Supervisor of GSR
2011 - 2014	Qing Liu Graduate Student Researcher	Supervisor of GSR
2010 - 2012	Nicholas Christian Graduate Student Researcher	Supervisor of GSR
2010 - 2012	Kelley Kidwell Graduate Student Researcher	Supervisor of GSR
2007 - 2008	Sarah Haile Graduate Student Researcher	Supervisor of GSR
2004 - 2007	Hanna Bandos Graduate Student Researcher	Supervisor of GSR
2004 - 2006	Scott Dean Graduate Student Researcher	Supervisor of GSR

## MENTORING AND ADVISING

### Master's Students

Year(s)	Student's Name & Department/Degree/ Discipline	Role
2011 - 2012	Agimi, Yll MS (2012) Functional and Medical Impairments among hospitalized older-drivers	Essay Committee Member

2009 - 2010	Tang, Shaowu MS (2010) Inference on median failure time for censored survival data	Primary Advisor, Chair Essay Committee
2008 - 2009	Glover, Khaleelah MS (2009) Is there a difference in completeness of radiation treatment when comparing African American and Caucasian Women?	Essay Committee Member
2007 - 2008	Wenchi, Wu MS (2008) Estimating the probability of Lymphedema following breast cancer surgery	Essay Committee Member
2004 - 2005	Rizzo, Sara MS (2005) Syndromic surveillance for the early detection of influenza outbreaks	Primary Advisor, Chair Essay Committee
2003 - 2004	Sundry, Reena MS (2004) Psychometric Evaluation of NSABP C-07 Neurotoxicity self-administered Questionnaire	Primary Advisor, Chair Essay Committee
2003 - 2004	Ko, Feng-shou MS (2004) A method to identify potential longitudinal biomarkers for survival	Primary Advisor, Chair Essay Committee
2002 - 2003	Famili, Pouran MPH (2003) Prostate cancer, androgen deprivation and the risk of periodontal disease studies	Essay Committee Member
2002 - 2003	Gao, Weimin MS (2003) Statistical Properties of Tree-structure models for survival data	Essay Committee Member
2002 - 2003	Kao, Amy MPH (2003)	Essay Committee Member

Cardiopulmonary manifestations of systemic lupus erythematosus; evaluation and management

1995 - 1996	Garratt, Lorraine MS (1996) Factor composition of the Cannon-Spoor Premorbid Adjustment Scale and the Implications of a multidimensional model	Primary Advisor, Chair Essay Committee
1994 - 1995	Sledak, Suzanne MS (1995) Environmental tobacco smoke exposure and illness in young children	Primary Advisor, Chair Essay Committee
1991 - 1992	Sankey, Scott MS (1992) The association between pollution and respiratory hospital admissions in Allegheny County, Pennsylvania	Primary Advisor, Chair Essay Committee
1991 - 1992	Johnson, Elizabeth MS (1992) Assessment of factors associated with Rhabdomyosarsoma	Primary Advisor, Chair Essay Committee
1991 - 1992	Cecchetti, Alfred MS (1992) Prediction of mortality from summary electrocardiogram parameters	Primary Advisor
1991 - 1992	Similo, Shari MS (1992) An analysis of prognostic indicators of chronic rejection of lung transplants	Primary Advisor, Chair Essay Committee
1991 - 1992	Van Praagh, Andrew D. MSc Hyg (1992) Giardiasis detection by a commercial elisa, ProSpec T/giardia	Essay Committee Member
1991 - 1992	DeSensi, Elizabeth MSc Hyg (1992) Assessment of factors associated with rhabdomyosarsoma	Essay Committee Member

1990 - 1991	Jones, Judy MSc Hyg (1991) The effect of blood transfusion on disease-free survival and survival of patients with colon cancer	Essay Committee Member
1989 - 1990	Kasian, Charlene MSc Hyg (1990) Evaluation of microbial resistance through production of beta-lactamase in otitis media pathogens	Essay Committee Member
1989 - 1990	Kemp, Margaret MSc Hyg (1990) Cancer clusters: an approach to study for the occupational physician	Essay Committee Member
1988 - 1989	Dignam, James MSc Hyg (1989) A comparison of survival between black and white female breast cancer patients participating in NSABP randomized clinical trials.	Essay Committee Member
1988 - 1989	Bearden, Audrey MSc Hyg (1989) Cause-Specific mortality in non-Allegheny County coke oven workers	Primary Advisor, Chair Essay Committee
1988 - 1989	Diklah, Ron MSc Hyg (1989) Methods to control for normal mortality risk in a study with long-term follow-up; comparison of the relative and the adjusted survival rates	Essay Committee Member
1986 - 1987	Beres, Leslie MSc Hyg (1987) A comparative analysis of growth curve modeling in a population of cleft-palate children	Essay Committee Member
1985 - 1986	Lyons, Ella MSc Hyg (1986) Assessing multiple endpoints associated with occupational exposure: a multivariate	Essay Committee Member

approach with application to a sample of chemical workers

1984 - 1985	Ubringer, Elizabeth MSc Hyg (1985) The Cauchy distribution as an alternative to the normal for certian biomedical measurements	Essay Committee Member
-------------	--	------------------------

**Doctoral Students**

<b>Year(s)</b>	<b>Student's Name &amp; Department/Degree/ Discipline</b>	<b>Role</b>
2014 - 2015	Sima Lopa PhD (2015) Inference on quantile residual life for length-biased survival data	Committee Member
2012 - 2013	Zhang, Yang PhD (2013) Statistical methods for classification based on dose response data: A modified EM algorithm for regression analysis of missing data	Dissertation Committee Member
2012 - 2014	Qing Liu PhD (2014) Dynamic prediction in competing risks	Dissertation Committee Member
2011 - 2013	Tu, Li-Chaun PhD (2013) Use of bias coin methodology for randomization in clinical trials	Primary Advisor, Chair Dissertation Committee
2010 - 2012	Kidwell, Kelly PhD (2012) Survival analysis of shared-path adaptive treatment strategies	Dissertation Committee Member
2008 - 2010	Tang, Xinyu PhD (2010) Analyzing survival data from sequentially randomized designs	Dissertation Committee Member
2008 - 2010	Yuan, Xing PhD (2010) A meta-analytic framework for combining incomparable Cox proportional hazard	Dissertation Committee Member

models caused by omitting important covariates

2007 - 2009	Kong, Yuan PhD (2009) Prediction of accrual closure date in multi-center clinical trials with Poisson process models	Dissertation Committee Member
2007 - 2009	Glad, Jo Ann PhD (2009) Association of emergency room visits for asthma with air quality in Allegheny County	Dissertation Committee Member
2006 - 2008	Haile, Sarah PhD (2008) Inference on competing risk in breast cancer data	Dissertation Committee Member
2005 - 2007	Bandos, Hanna PhD (2007) Inference on median residual life function for censored survival data	Dissertation Committee Member
2004 - 2006	Simpson, Jennifer PhD (2006) Estrogen metabolism, breast density and breast cancer	Dissertation Committee Member
2004 - 2006	El-Saed, Aiman PhD (2006) Geographic variations in stroke incidence and mortality among older populations in four U.S. communities	Dissertation Committee Member
2002 - 2004	Wojnakowski, Mary PhD (2004) Study of risk factors for post-operative pulmonary complications	Dissertation Committee Member
2002 - 2004	Ruppert, Kristine DrPH (2004) Assessment of the potential ascertainment bias associated with the use of biopsies from non-systematic follow-up of liver transplant patients	Primary Advisor, Chair Dissertation Committee

2001 - 2003	Mor, Maria Katrina PhD (2003) A Bayesian group sequential approach for multiple endpoints	Dissertation Committee Member
2001 - 2003	Agatisa, Patricia PhD (2003) Impairment of endothelial function in women with a history of preeclampsia; an indicator of cardiovascular risk	Dissertation Committee Member
1999 - 2001	Gaus, Christine PhD (2001) Methods for combining covariate data obtained by multiple sampling schemes in occupational cohort	Dissertation Committee Member
1999 - 2001	Gathuru, Irene PhD (2001) The assessment of environmental and socioeconomic factors with respiratory health in Nigerian families	Dissertation Committee Member
1999 - 2001	Remsberg, Karen PhD (2001) Determining the prevalence of early male pattern baldness and risk of coronary heart disease in brothers of women with poly-cystic ovary syndrome	Dissertation Committee Member
1999 - 2001	Swan, Monica PhD (2001) Violent behavior among youth drinkers: pattern and predictors	Dissertation Committee Member
1998 - 2000	Rea, Nancy PhD (2000) Evaluation of the Erie County immunization registry of children 12 to 23 months of age	Dissertation Committee Member
1998 - 2000	Zbrowski, Jeanne PhD (2000) Bone mineral density among women with polycystic ovary syndrome	Dissertation Committee Member

1998 - 2000	Chen, Wei PhD (2000) Utilization of compliance information in clinical trials. A new methodology	Primary Advisor, Chair Dissertation Committee
1997 - 1999	Ngo, Duyen L. PhD (1999) Bone mineral density, breast density and sex steroid hormones in older women	Dissertation Committee Member
1996 - 1998	Cunningham, Albert PhD (1998) An expert system to assess the effect of molecular modification on drug response	Dissertation Committee Member
1996 - 1998	Pandalai, Sudha P. PhD (1998) The relationship of psychopathology, psychosocial, family and neurological course of illness factors to relapse in of schizophrenia	Dissertation Committee Member
1996 - 1998	Sankey, Scott PhD (1998) Meta-analysis with sparse data, dichotomized discrete outcomes, and linear regression applied to ordinal data	Dissertation Committee Member
1996 - 1998	Twal, Marie McConville DrPH (1998) Women's perceptions of the value of genetic screening at different life stages	Dissertation Committee Member
1996 - 1998	Zeigler-Johnson, Charnita PhD (1998) Homocysteine and leptin levels in African-American women as related to subclinical atherosclerosis	Dissertation Committee Member
1995 - 1997	Lieb, Anita PhD (1997) Comparison of variances estimates of the standard mortality ratio in the presence of small comparison populations	Dissertation Committee Member
1995 - 1997	Landsittel, Douglas PhD (1997)	Dissertation Committee Member

A simulation study of statistical modeling  
with neural networks

1994 - 1996	Lee, Eunyong Choi PhD (1996) The additive hazards model and its application to the analysis of censored data	Dissertation Committee Member
1994 - 1996	Youk, Ada Owens PhD (1996) Iterative allocation of partially classified data in epidemiologic studies	Dissertation Committee Member
1992 - 1994	Dignam, James PhD (1994) Multiple endpoint problems in survival analysis	Dissertation Committee Member
1992 - 1994	Boylstein, Lee Ann PhD (1994) Comparison and evaluation of smoothing methods and their application to toxicological bioassays	Dissertation Committee Member
1992 - 1994	Markovic, Nina PhD (1994) Socio-economic status and John Henryism: Associations with blood Pressure in a Nigerian civil servant Population	Dissertation Committee Member
1991 - 1993	Massoudi, Mehran PhD (1993) The role of thyroid function in weight and cholesterol changes among menopausal women	Dissertation Committee Member
1991 - 1993	Houston, Sara PhD (1993) Electrocardiography left ventricular hypertrophy and related factors in Nigerians	Dissertation Committee Member
1991 - 1993	McDonald, Margaret PhD (1993) Evaluation of the D/ART Training Program	Dissertation Committee Member

1991 - 1993	Nowalk, May P. PhD (1993) An analysis of nutrient intake, eating behaviors, and risk for coronary heart disease in premenopausal women	Dissertation Committee Member
1989 - 1991	Kim, Min Shik DrPH (1991) The relationship between risk factors and the mentally ill homeless: predictors of homelessness in the mentally ill	Dissertation Committee Member
1989 - 1991	Valencia, Ramos G. DrPH (1991) Covariates associated with neonatal and post-neonatal mortality: The case of Peru	Primary Advisor, Chair Essay Committee
1988 - 1990	Hussein, Mohamed PhD (1990) Procedure for stopping long-term clinical trials via requiring "r" rejections out of "n" multiple looks to control elevation of type I error	Dissertation Committee Member
1988 - 1990	Slesinski, Mary Jane PhD (1990) An epidemiologic study of lipid levels in adult cystic fibrosis patients	Dissertation Committee Member
1987 - 1989	Ferris, Denise DrPH (1989) Nutritional status of vegetarians	Dissertation Committee Member

## SERVICE

### Service to Internal Organizations

#### Department Committees

2014 - 2015	Member, Search Committee for New Faculty Members in the Department of Biostatistics
2012 - 2013	Member, Search Committee for Two New Tenure-Track Faculty Positions in the Department of Biostatistics
2012 - 2013	Chair, Search Committee for Research Assistant Professor Position in the Department of Biostatistics
2009 - 2009	Chair, Search Committee for Director of the UPCI Biostatistical Facility

1993 - 2005	Member, Department of Biostatistics Budget and Planning Committee
1991 - 1994	Department Representative, Doctoral Student Organization
1986 - 1987	Member, Executive Committee of the Department of Biostatistics NIH Shared Computer
1986 - 1988	Member, Computer Advisory Committee of the Pittsburgh Cancer Institute

### **School/University Committees**

2008 - 2012	Member, Faculty Representative, University of Pittsburgh Board of Trustee's Audit Committee
2007 - 2008	Member, GSPH Junior Faculty Oversight Committee for the Department of Human Genetics, Environmental and Occupational Health, and Infectious Disease and Microbiology.
2006 - 2007	Member, GSPH Search Committee for Director of the Epidemiology Data Center
2005 - 2006	Member, GSPH Search Committee for Dean of the Graduate School of Public Health
2004 - 2007	Member, GSPH Accreditation Committee
2003 - Present	Member, University of Pittsburgh Faculty Senate Council
2003 - Present	Member, University of Pittsburgh Faculty Assembly
2002 - 2003	Chair, GSPH Search Committee for the Chair of the Department of Epidemiology
2001 - 2005	Chair, GSPH Faculty Advancement, Promotion, Tenure Committee.
2001 - 2002	Member, GSPH Search Committee for Director of MMPH Program
2001 - 2002	Member, GSPH Ad Hoc Committee for Retreat Planning
2000 - 2001	Member, GSPH Search Committee for Dean of the Graduate School of Public Health, (Co-chair)
2000 - Present	Member, University of Pittsburgh Senate Computer Usage Committee
1999 - 2005	Member, President 2001-2002, GSPH Faculty Senate Executive Committee
1999 - 2005	Member, GSPH Council
1999 - 2005	Member, GSPH Budget Policy and Planning Committee
1996 - 2000	Member, GSPH Advisory Committee for the Joint MD/MPH Program
1996 - 2001	Member, University of Pittsburgh Faculty Senate Council
1995 - 2006	Member, GSPH Steering Committee for the Center for Public Health Practice,
1995 - 1997	Member, GSPH Committee for the Integrated Core Course in Public Health
1995 - 2001	Member, University of Pittsburgh Faculty Assembly
1993 - 1993	Member, GSPH Accreditation Committee
1991 - 1993	Chair, GSPH Educational Policies and Curriculum Committee
1991 - 1993	Member, GSPH School-wide Master's of Public Health Committee

1991 - 1997	Member, University of Pittsburgh Council for Graduate Study
1991 - 1997	Member, University of Pittsburgh Subcommittee on Evaluation of Academic Programs
1986 - 1994	Member, GSPH Alumni Executive Committee

**Service to External Organizations**

**Public Policy and Programs**

2014 - Present	Member, Statistical Advisor, Olympia Study Scientific Steering Committee, Olympia Study Scientific Steering Committee
2014 - Present	Statistical Advisor, National Cancer Institute, National Clinical Trial Network leadership Committee, National Clinical Trial Network Leadership Committee
2012 - 2013	Member, Statistical Advisor, Federal Drug Administration Panel on Innovations in Breast Cancer Drug Development
2012 - 2014	Member, National Cancer Institute, National Cancer Institute National Clinical Trials Network Working Group
2010 - 2011	Member, Statistical Advisor, National Cancer Institute Program for Assessment of Clinical Cancer Tests Clinical Assay Development Program Eligibility Criteria-Working Group 2.
2010 - 2011	Member, Statistical Advisor, National Cancer Institute Clinical Trials Planning Committee: Next generation trials for HER2-positive breast cancer. Rockville Maryland.
2010 - 2012	Member, Statistical Advisor, American Society of Clinical Oncology Expert Panel on 5-Alpha-Reductase Inhibitors
2009 - Present	Statistical Reviewer, National Cancer Institute, National Cancer Institute, Breast Cancer Steering Committee
2006 - 2006	Member, Statistical Advisor, National Cancer Institute's Working Group on the Feasibility of a Physical Activity, Weight Control Trial to Prevent Breast Cancer. Rockville, Maryland
2006 - 2008	Member, Statistical Advisor, American Society of Clinical Oncology Expert Panel on 5-Alpha-Reductase Inhibitors
2006 - 2009	Member, Statistical Advisor, Statistical Task Force of the American Joint Committee on Cancer
2006 - 2009	Member, Statistical Advisor, Foregut Task Force of the American Joint Committee on Cancer
2002	Member, Statistical Reviewer, Review Panel-National Cancer Institute, Small Grants Program for Cancer Epidemiology. Bethesda, Maryland.
2002 - 2003	Member, Statistical Advisor, Institute of Medicine's Committee on Assessing the Need for Clinical Trials of Testosterone Replacement Therapy.
1991 - 1997	Member, Statistical Advisor, Advisory Committee-NIEHS Program Project: Molecular Toxicology of Environmental Carcinogens. Columbia University.
1990	Member, Statistical Advisor, Special Review Committee-National Institute of Heart, Lung and Blood, Clinical Coordinating Center

for Asymptomatic Cardiac Ischemia Pilot Study. Bethesda, Maryland.

**Other Professional Activities**

- 2005 - Present      Member, Early Breast Cancer Trialist Cooperative Group  
Scientific Steering Committee
- 2005 - Present      Member, NSABP Foundation Board of Scientific Directors

NRG Oncology, Pittsburgh, PA, USA; University of Pittsburgh, Pittsburgh, PA, USA; Allegheny Health Network Cancer Institute, Pittsburgh, PA, USA. View Article and Find Full Text PDF. December 2019.Â and Data Management Center; Jong-Hyeon Jeong and Joseph P. Costantino, Graduate School of Public Health, University of Pittsburgh; Priya Rastogi, University of Pittsburgh Cancer Institute; D. Lawrence Wickerham and Norman Wolmark, Allegheny Cancer Center, Allegheny General Hospital, Pittsburgh, PA; Louis Fehrenbacher, Kaiser-Permanente, Northern California, Vallejo, CA; Eleftherios P. Mamounas, UF Health Cancer Center, Orlando Health, Orlando, FL; Sandra M. Swain, Washington. The University of Pittsburgh is a public research university best known for its achievements in STEM, such as helping defeat polio, leading the world in organ transplantation and pioneering TV. Undergrads are encouraged to delve into research projects with initiatives such as the Department of Neuroscienceâ€™s Summer Undergraduate Research Internship and several Summer Research Programs in the Swanson School of Engineering. The academic scholarships offered range in value for first-year students from \$2,000 per year to full. tuition and room and board, with 55% of students receiving aid in grants or scholarships. University of Pittsburgh Panthers can choose between more than 350... The University of Pittsburgh (Pitt) is a state-related public research university in Pittsburgh, Pennsylvania, United States. The university is composed of 17 undergraduate and graduate schools and colleges at its urban Pittsburgh campus, home to the university's central administration and 28,391 undergraduate and graduate students. The 132-acre Pittsburgh campus includes various historic buildings that are part of the Schenley Farms Historic District, most notably its 42-story Gothic revival...